

Table 1.4
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

All Races

Site	Incidence ^a (2004-2008)			US Mortality ^b (2004-2008)			Survival ^c (%) (2001-2007)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	464.4	541.0	411.6	181.3	223.0	153.2	65.3	66.0	64.7
Oral Cavity & Pharynx:	10.6	15.7	6.2	2.5	3.9	1.4	60.8	59.8	62.9
Lip	0.7	1.2	0.3	0.0	0.0	0.0	90.5	90.8	89.8
Tongue	3.0	4.5	1.7	0.6	0.9	0.4	59.4	59.5	59.1
Salivary gland	1.3	1.7	1.0	0.2	0.4	0.1	71.3	64.7	79.8
Floor of mouth	0.6	0.9	0.3	0.0	0.1	0.0	51.2	48.7	57.4
Gum & other oral cavity	1.5	1.8	1.2	0.4	0.5	0.3	58.1	55.1	61.7
Nasopharynx	0.7	1.0	0.4	0.2	0.3	0.1	58.3	57.7	59.5
Tonsil	1.6	2.7	0.6	0.2	0.3	0.1	67.8	68.5	64.5
Oropharynx	0.4	0.6	0.2	0.2	0.3	0.1	38.0	39.3	34.1
Hypopharynx	0.7	1.1	0.2	0.1	0.2	0.0	30.2	30.2	30.8
Other oral cavity & pharynx	0.2	0.3	0.1	0.5	0.9	0.2	35.8	39.3	26.5
Digestive System:	86.9	106.4	71.3	43.6	56.1	33.8	44.4	42.7	46.3
Esophagus	4.5	7.8	1.9	4.3	7.8	1.6	16.8	16.8	16.8
Stomach	7.7	10.8	5.4	3.7	5.2	2.7	26.3	24.5	29.0
Small intestine	2.0	2.4	1.6	0.4	0.5	0.3	63.2	63.8	62.4
Colon & Rectum:	47.2	55.0	41.0	17.1	20.7	14.5	64.3	64.6	64.0
Colon	33.9	38.3	30.6	-	-	-	63.6	64.0	63.2
Rectum	13.2	16.7	10.4	-	-	-	66.0	65.8	66.2
Anus, anal canal & anorectum	1.6	1.4	1.8	0.2	0.2	0.2	64.9	59.8	68.2
Liver & intrahep. bile duct:	7.3	11.2	3.9	5.3	7.9	3.2	14.4	14.4	14.4
Liver	6.7	10.6	3.3	4.1	6.5	2.2	15.2	14.9	15.7
Intrahepatic bile duct	0.6	0.7	0.6	1.2	1.4	1.1	5.4	4.9	6.0
Gallbladder	1.2	0.8	1.5	0.6	0.5	0.8	16.5	14.2	17.4
Other biliary	1.8	2.3	1.5	0.5	0.5	0.4	15.5	16.4	14.5
Pancreas	12.0	13.6	10.7	10.8	12.5	9.4	5.5	5.1	5.8
Retroperitoneum	0.4	0.4	0.4	0.1	0.1	0.1	50.2	47.8	52.5
Peritoneum, omentum & mesentery	0.7	0.1	1.2	0.3	0.1	0.4	28.6	39.7	27.9
Other digestive system	0.5	0.6	0.5	0.3	0.3	0.2	10.5	10.3	10.8
Respiratory System:	66.3	82.5	54.3	53.1	70.0	40.8	18.7	18.1	19.5
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.2	0.2	0.1	56.2	56.0	56.5
Larynx	3.4	6.0	1.3	1.2	2.2	0.5	60.8	61.8	56.7
Lung & bronchus	62.0	75.2	52.3	51.6	67.4	40.1	15.6	13.5	18.0
Pleura ^d	0.0	0.0	0.0	0.1	0.1	0.0	24.8	21.0	31.5
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.0	49.8	53.2	40.6
Bones & joints	0.9	1.0	0.8	0.4	0.5	0.4	66.3	63.7	69.5
Soft tissue (including heart)	3.3	3.9	2.8	1.3	1.5	1.1	66.1	65.6	66.7
Skin (excl. basal & squamous):	22.7	29.4	18.1	3.5	5.5	2.1	90.8	88.7	93.4
Melanoma of the skin	20.8	26.7	16.7	2.7	4.0	1.7	91.2	89.2	93.7
Other non-epithelial skin	1.9	2.6	1.5	0.8	1.5	0.4	85.9	83.0	89.4
Breast	67.0	1.2	124.0	13.2	0.3	23.5	89.1	85.7	89.1
Breast (<i>in situ</i>)	16.4	0.2	30.9	-	-	-	100.0	100.0	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 17 areas. Based on follow-up of patients into 2008.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.4 - continued
 Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
 By Primary Cancer Site, Sex and Time Period

All Races

Site	Incidence ^a (2004-2008)			US Mortality ^b (2004-2008)			Survival ^c (%) (2001-2007)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	26.0	-	48.6	8.9	-	15.9	68.1	-	68.1
Cervix uteri	4.2	-	8.1	1.3	-	2.4	68.6	-	68.6
Corpus uteri	12.5	-	23.4	1.1	-	1.9	83.1	-	83.1
Uterus, NOS	0.3	-	0.6	1.3	-	2.2	25.9	-	25.9
Ovary ^d	6.9	-	12.8	4.7	-	8.4	43.8	-	43.8
Vagina	0.4	-	0.7	0.1	-	0.2	50.2	-	50.2
Vulva	1.3	-	2.3	0.3	-	0.5	72.7	-	72.7
Other female genital system	0.4	-	0.8	0.1	-	0.2	61.1	-	61.1
Male Genital System:	72.9	162.6	-	9.5	24.8	-	99.1	99.1	-
Prostate	69.7	156.0	-	9.3	24.4	-	99.4	99.4	-
Testis	2.8	5.5	-	0.1	0.2	-	95.3	95.3	-
Penis	0.4	0.8	-	0.1	0.2	-	64.1	64.1	-
Other male genital system	0.1	0.2	-	0.0	0.0	-	88.7	88.7	-
Urinary System:	36.6	58.8	20.0	8.7	13.9	5.0	74.1	75.8	70.5
Urinary bladder	21.1	37.5	9.2	4.4	7.7	2.2	78.1	79.9	72.6
Kidney & renal pelvis	14.6	20.0	10.2	4.0	5.9	2.7	69.5	69.5	69.4
Ureter	0.6	0.8	0.4	0.1	0.2	0.1	51.0	53.5	47.6
Other urinary system	0.3	0.5	0.2	0.1	0.2	0.1	51.7	54.9	46.7
Eye & Orbit	0.8	1.0	0.7	0.1	0.1	0.1	82.4	81.0	83.9
Brain & Nervous System: ^e	6.5	7.7	5.4	4.3	5.2	3.5	33.4	31.8	35.4
Brain	6.1	7.3	5.0	-	-	-	30.2	29.1	31.4
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	79.6	75.6	83.0
Endocrine System:	11.7	6.4	17.0	0.8	0.8	0.8	94.8	89.7	96.6
Thyroid	11.0	5.6	16.3	0.5	0.5	0.5	97.2	94.2	98.1
Other endocrine & thymus	0.7	0.9	0.6	0.3	0.3	0.3	62.9	64.0	61.4
Lymphoma:	22.7	27.1	19.1	7.1	9.1	5.7	69.7	68.2	71.3
Hodgkin lymphoma	2.8	3.1	2.6	0.4	0.5	0.3	83.9	82.8	85.2
Non-Hodgkin lymphoma	19.8	24.0	16.5	6.7	8.6	5.4	67.3	65.7	69.0
Myeloma	5.7	7.2	4.6	3.5	4.4	2.8	39.7	40.6	38.6
Leukemia:	12.5	16.1	9.7	7.1	9.7	5.4	53.9	54.2	53.5
Lymphocytic:	6.3	8.4	4.6	2.0	2.9	1.4	74.1	73.7	74.8
Acute lymphocytic	1.7	1.9	1.4	0.5	0.6	0.4	64.4	64.1	64.9
Chronic lymphocytic	4.2	5.8	3.0	1.4	2.1	0.9	78.0	76.6	80.2
Other lymphocytic	0.4	0.7	0.2	0.1	0.2	0.1	80.4	85.9	66.2
Myeloid & Monocytic:	5.5	6.9	4.5	3.4	4.4	2.6	32.8	32.2	33.6
Acute myeloid	3.5	4.3	3.0	2.8	3.6	2.2	22.6	21.2	24.2
Chronic myeloid	1.6	2.0	1.2	0.3	0.5	0.3	57.2	56.8	57.6
Acute monocytic	0.3	0.3	0.2	0.0	0.0	0.0	24.0	23.4	24.5
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.1	30.8	29.4	32.4
Other leukemia:	0.7	0.8	0.6	1.8	2.3	1.3	26.1	25.8	26.5
Other acute leukemia	0.3	0.3	0.2	0.7	0.9	0.6	15.6	16.6	14.4
Aleukemic, subleukemic & NOS	0.4	0.5	0.3	1.0	1.4	0.8	34.3	33.1	35.7
Kaposi Sarcoma ^f	0.6	1.2	0.1	-	-	-	67.6	67.4	68.2
Mesothelioma ^f	1.1	1.9	0.4	-	-	-	7.7	5.9	13.6
Ill-defined & unspecified	9.5	10.9	8.5	13.7	17.3	11.0	16.2	19.9	12.7

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 17 areas. Based on follow-up of patients into 2008.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.5
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence ^a (2004-2008)			US Mortality ^b (2004-2008)			Survival ^c (%) (2001-2007)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	471.8	543.6	423.0	180.0	220.0	152.8	66.0	66.5	65.6
Oral Cavity & Pharynx:	10.8	16.1	6.2	2.4	3.7	1.4	62.4	62.0	63.2
Lip	0.8	1.4	0.4	0.0	0.0	0.0	90.5	90.7	89.7
Tongue	3.2	4.7	1.8	0.6	0.9	0.4	61.4	61.8	60.3
Salivary gland	1.3	1.8	1.0	0.2	0.4	0.1	69.8	63.3	78.9
Floor of mouth	0.6	0.9	0.3	0.0	0.1	0.0	52.6	50.3	58.0
Gum & other oral cavity	1.5	1.8	1.2	0.4	0.4	0.3	59.0	56.7	61.6
Nasopharynx	0.4	0.6	0.3	0.2	0.2	0.1	52.2	53.3	49.4
Tonsil	1.7	2.9	0.6	0.2	0.3	0.1	70.3	71.2	66.2
Oropharynx	0.4	0.6	0.2	0.2	0.3	0.1	42.3	43.8	37.6
Hypopharynx	0.6	1.1	0.3	0.1	0.2	0.0	32.5	32.7	32.1
Other oral cavity & pharynx	0.2	0.3	0.1	0.5	0.8	0.2	38.4	42.5	27.5
Digestive System:	84.2	103.1	69.0	42.0	54.1	32.4	45.3	43.8	47.0
Esophagus	4.7	8.1	1.8	4.4	7.9	1.6	17.7	17.8	17.4
Stomach	6.8	9.5	4.6	3.2	4.5	2.3	24.8	23.2	27.5
Small intestine	1.9	2.4	1.6	0.3	0.4	0.3	64.6	65.8	63.1
Colon & Rectum:	46.5	54.4	40.2	16.6	20.1	14.0	65.0	65.5	64.5
Colon	33.5	38.0	30.0	-	-	-	64.5	65.1	64.0
Rectum	13.0	16.4	10.2	-	-	-	66.3	66.3	66.3
Anus, anal canal & anorectum	1.8	1.5	2.0	0.2	0.2	0.2	66.0	61.0	69.2
Liver & Intrahep. bile duct:	6.2	9.6	3.3	4.9	7.2	3.0	13.9	14.1	13.5
Liver	5.6	8.9	2.7	3.7	5.8	2.0	14.8	14.8	15.0
Intrahepatic bile duct	0.6	0.6	0.5	1.2	1.4	1.1	5.3	5.3	5.4
Gallbladder	1.1	0.8	1.4	0.6	0.4	0.7	16.4	13.6	17.6
Other biliary	1.8	2.2	1.5	0.5	0.5	0.4	15.5	17.0	14.0
Pancreas	11.9	13.5	10.5	10.6	12.4	9.2	5.5	5.2	5.7
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	50.2	47.6	52.9
Peritoneum, omentum & mesentery	0.7	0.1	1.3	0.3	0.1	0.4	28.6	35.7	28.2
Other digestive system	0.5	0.6	0.5	0.3	0.3	0.2	9.8	9.6	10.0
Respiratory System:	67.7	82.5	56.6	53.5	69.4	41.8	18.9	18.3	19.7
Nose, nasal cavity & middle ear	0.7	0.9	0.6	0.2	0.2	0.1	55.6	55.5	55.7
Larynx	3.4	6.0	1.3	1.1	2.0	0.4	61.8	62.8	58.0
Lung & bronchus	63.3	75.3	54.6	52.1	66.9	41.2	15.9	13.7	18.3
Pleura ^d	0.0	0.1	0.0	0.1	0.1	0.0	23.9	19.3	33.2
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.0	49.6	54.1	37.4
Bones & joints	1.0	1.1	0.8	0.5	0.5	0.4	66.1	62.7	70.5
Soft tissue (including heart)	3.3	4.0	2.8	1.3	1.5	1.1	66.6	66.0	67.4
Skin (excl. basal & squamous):	26.3	33.7	21.2	4.0	6.1	2.4	90.5	88.3	93.1
Melanoma of the skin	24.3	30.9	19.7	3.1	4.6	2.0	90.9	88.9	93.5
Other non-epithelial skin	2.0	2.8	1.4	0.9	1.5	0.4	84.3	81.2	88.3
Breast	68.2	1.2	127.3	12.8	0.3	22.8	90.3	86.5	90.4
Breast (<i>in situ</i>)	16.5	0.1	31.4	-	-	-	100.0	100.0	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 17 areas. Based on follow-up of patients into 2008.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.5 - continued
 Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
 By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence ^a (2004-2008)			US Mortality ^b (2004-2008)			Survival ^c (%) (2001-2007)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	26.6	-	50.2	8.7	-	15.7	69.2	-	69.2
Cervix uteri	4.0	-	8.0	1.2	-	2.2	70.0	-	70.0
Corpus uteri	12.9	-	24.3	1.0	-	1.8	84.9	-	84.9
Uterus, NOS	0.3	-	0.5	1.2	-	2.1	25.5	-	25.5
Ovary ^d	7.2	-	13.5	4.9	-	8.8	43.7	-	43.7
Vagina	0.4	-	0.7	0.1	-	0.2	50.9	-	50.9
Vulva	1.3	-	2.4	0.3	-	0.5	72.8	-	72.8
Other female genital system	0.4	-	0.8	0.1	-	0.2	61.1	-	61.1
Male Genital System:	71.2	157.0	-	8.8	22.9	-	99.4	99.4	-
Prostate	67.4	149.5	-	8.6	22.4	-	99.7	99.7	-
Testis	3.3	6.5	-	0.1	0.3	-	95.7	95.7	-
Penis	0.4	0.8	-	0.1	0.2	-	63.2	63.2	-
Other male genital system	0.1	0.2	-	0.0	0.0	-	91.9	91.9	-
Urinary System:	38.9	62.5	20.9	8.9	14.3	5.1	74.7	76.1	71.3
Urinary bladder	22.9	40.6	9.8	4.6	8.0	2.2	78.5	80.1	73.8
Kidney & renal pelvis	15.1	20.5	10.5	4.1	6.0	2.7	69.7	69.7	69.8
Ureter	0.6	0.9	0.4	0.1	0.2	0.1	50.8	54.0	46.4
Other urinary system	0.3	0.5	0.2	0.1	0.2	0.1	53.0	55.0	49.5
Eye & Orbit	0.9	1.1	0.8	0.1	0.1	0.1	82.4	80.8	84.0
Brain & Nervous System: ^e	7.1	8.4	5.9	4.6	5.6	3.8	32.5	31.2	34.2
Brain	6.7	8.0	5.5	-	-	-	29.3	28.6	30.3
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	80.8	76.7	84.3
Endocrine System:	12.2	6.7	17.8	0.8	0.8	0.7	95.2	90.3	96.9
Thyroid	11.5	5.9	17.2	0.5	0.5	0.5	97.5	94.4	98.3
Other endocrine & thymus	0.7	0.8	0.6	0.3	0.3	0.3	62.6	64.6	60.2
Lymphoma:	23.7	28.3	20.0	7.4	9.4	5.9	70.3	69.1	71.6
Hodgkin lymphoma	3.0	3.3	2.8	0.4	0.5	0.3	84.3	83.3	85.4
Non-Hodgkin lymphoma	20.7	25.0	17.3	7.0	8.9	5.6	67.9	66.7	69.3
Myeloma	5.3	6.8	4.1	3.2	4.2	2.6	39.5	40.8	37.9
Leukemia:	13.1	16.8	10.2	7.4	9.9	5.5	54.0	54.2	53.8
Lymphocytic:	6.8	8.9	5.0	2.1	3.0	1.5	74.3	73.8	75.1
Acute lymphocytic	1.8	2.0	1.6	0.5	0.6	0.4	64.3	63.9	64.7
Chronic lymphocytic	4.5	6.2	3.2	1.5	2.2	1.0	78.1	76.5	80.5
Other lymphocytic	0.5	0.7	0.2	0.1	0.2	0.1	80.8	86.4	66.3
Myeloid & Monocytic:	5.7	7.1	4.6	3.5	4.6	2.7	31.8	31.1	32.7
Acute myeloid	3.6	4.5	3.0	2.9	3.8	2.3	21.9	20.6	23.5
Chronic myeloid	1.6	2.0	1.2	0.3	0.5	0.3	55.7	55.1	56.4
Acute monocytic	0.3	0.4	0.3	0.0	0.0	0.0	24.4	22.8	26.0
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.1	29.2	28.8	29.7
Other leukemia:	0.7	0.8	0.5	1.8	2.4	1.4	24.8	24.2	25.6
Other acute leukemia	0.3	0.3	0.2	0.7	1.0	0.6	14.0	14.5	13.4
Aleukemic, subleukemic & NOS	0.4	0.5	0.3	1.0	1.4	0.8	33.6	32.5	34.8
Kaposi Sarcoma ^f	0.5	1.0	0.1	-	-	-	72.2	71.6	77.4
Mesothelioma ^f	1.2	2.1	0.5	-	-	-	7.1	5.4	13.0
Ill-defined & unspecified	9.6	11.0	8.6	13.6	17.2	11.0	16.7	21.0	12.8

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 17 areas. Based on follow-up of patients into 2008.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.6
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Blacks								
	Incidence ^a (2004-2008)			US Mortality ^b (2004-2008)			Survival ^c (%) (2001-2007)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	491.2	626.1	400.9	220.8	295.3	177.7	57.8	61.1	54.0
Oral Cavity & Pharynx:	9.9	15.6	5.6	3.4	6.0	1.5	42.1	37.3	52.6
Lip	0.1	0.1	-	-	-	-	85.5	79.3	89.5
Tongue	2.3	3.7	1.2	0.6	1.1	0.3	33.0	30.5	38.1
Salivary gland	1.0	1.0	1.0	0.2	0.2	0.1	72.9	66.7	78.1
Floor of mouth	0.6	1.0	0.3	0.0	0.1	0.0	39.5	36.0	51.3
Gum & other oral cavity	1.5	1.9	1.3	0.4	0.6	0.2	51.2	41.4	64.1
Nasopharynx	0.7	1.2	0.3	0.3	0.5	0.2	53.7	50.0	62.3
Tonsil	1.7	3.0	0.6	0.3	0.5	0.1	45.3	44.2	49.4
Oropharynx	0.6	1.2	0.3	0.4	0.7	0.2	17.8	18.3	14.5
Hypopharynx	1.1	2.1	0.3	0.2	0.4	0.1	19.7	19.2	21.8
Other oral cavity & pharynx	0.3	0.5	0.2	0.9	1.8	0.4	21.4	23.1	15.3
Digestive System:	109.4	135.4	90.9	59.9	79.4	46.7	38.1	34.9	41.4
Esophagus	5.1	8.6	2.7	4.9	8.5	2.4	11.2	10.5	12.9
Stomach	11.9	17.2	8.5	7.2	10.7	5.0	25.5	22.5	29.4
Small intestine	3.1	3.5	2.7	0.6	0.7	0.5	57.8	54.6	60.6
Colon & Rectum:	57.8	67.7	51.2	24.3	30.5	20.4	56.0	55.0	56.9
Colon	43.9	50.1	39.7	-	-	-	55.2	54.4	55.8
Rectum	14.0	17.5	11.5	-	-	-	58.5	56.4	60.4
Anus, anal canal & anorectum	1.8	1.9	1.7	0.2	0.2	0.2	55.0	49.8	60.1
Liver & Intrahep. bile duct:	9.2	15.1	4.6	7.1	11.5	3.9	9.9	8.3	14.2
Liver	8.6	14.6	4.0	6.0	10.2	2.9	10.1	8.5	14.7
Intrahepatic bile duct	0.5	0.5	0.6	1.1	1.3	1.0	6.1	0.0	9.1
Gallbladder	1.5	1.1	1.8	0.8	0.7	1.0	14.2	18.9	12.5
Other biliary	1.7	2.0	1.5	0.4	0.4	0.4	12.2	10.5	14.3
Pancreas	15.9	17.1	14.8	13.9	15.6	12.5	4.4	3.8	5.0
Retroperitoneum	0.4	0.3	0.4	0.1	0.1	0.1	46.5	37.0	51.3
Peritoneum, omentum & mesentery	0.4	0.1	0.5	0.2	0.1	0.2	30.5	66.1	23.3
Other digestive system	0.7	0.8	0.6	0.4	0.5	0.3	14.8	13.9	15.0
Respiratory System:	78.8	110.9	57.3	59.5	90.1	39.7	16.5	16.6	16.3
Nose, nasal cavity & middle ear	0.7	1.0	0.5	0.2	0.2	0.1	54.0	52.0	57.3
Larynx	5.2	9.8	1.9	2.2	4.4	0.7	53.2	54.7	47.1
Lung & bronchus	72.7	99.8	54.7	57.0	85.4	38.8	12.9	11.6	14.5
Pleura ^d	-	-	-	0.0	0.1	0.0	-	-	-
Trachea & other respiratory organs	0.2	0.2	0.1	0.1	0.1	0.1	50.7	47.3	54.8
Bones & joints	0.7	0.8	0.7	0.5	0.6	0.4	64.1	65.0	62.9
Soft tissue (including heart)	3.3	3.6	3.1	1.4	1.4	1.4	61.7	61.1	62.3
Skin (excl. basal & squamous):	2.2	2.2	2.2	1.0	1.4	0.6	85.2	82.6	87.0
Melanoma of the skin	1.0	1.2	0.9	0.4	0.5	0.4	72.4	65.2	77.4
Other non-epithelial skin	1.2	1.1	1.2	0.5	0.9	0.2	94.3	94.4	94.0
Breast	68.8	1.6	119.9	19.0	0.5	32.0	77.0	76.8	77.0
Breast (<i>in situ</i>)	16.4	0.2	28.8	-	-	-	100.0	98.7	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 17 areas. Based on follow-up of patients into 2008.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.6 - continued
 Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
 By Primary Cancer Site, Sex and Time Period

Site	Blacks								
	Incidence ^a (2004-2008)			US Mortality ^b (2004-2008)			Survival ^c (%) (2001-2007)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	25.3	-	44.4	11.6	-	19.4	54.0	-	54.0
Cervix uteri	5.6	-	10.0	2.5	-	4.3	58.4	-	58.4
Corpus uteri	11.3	-	19.7	1.8	-	3.0	61.9	-	61.9
Uterus, NOS	0.7	-	1.2	2.5	-	4.2	27.6	-	27.6
Ovary ^d	5.8	-	10.0	4.2	-	7.0	34.9	-	34.9
Vagina	0.6	-	1.0	0.2	-	0.3	46.2	-	46.2
Vulva	1.0	-	1.8	0.2	-	0.3	66.7	-	66.7
Other female genital system	0.4	-	0.7	0.1	-	0.2	55.6	-	55.6
Male Genital System:	98.5	236.4	-	19.1	55.4	-	96.0	96.0	-
Prostate	97.4	233.8	-	19.0	54.9	-	96.2	96.2	-
Testis	0.6	1.3	-	0.1	0.1	-	86.5	86.5	-
Penis	0.4	1.0	-	0.1	0.3	-	61.7	61.7	-
Other male genital system	0.1	0.2	-	0.0	0.0	-	70.3	70.3	-
Urinary System:	30.3	45.9	19.7	7.9	11.7	5.5	64.9	67.8	60.5
Urinary bladder	13.1	21.6	7.6	3.7	5.5	2.7	64.4	70.3	54.0
Kidney & renal pelvis	16.5	23.3	11.6	4.0	6.0	2.6	66.2	66.6	65.6
Ureter	0.3	0.4	0.3	0.0	0.1	0.0	42.3	38.7	46.9
Other urinary system	0.4	0.6	0.3	0.1	0.1	0.2	35.2	36.9	33.8
Eye & Orbit	0.2	0.3	0.2	0.0	0.0	0.0	73.7	74.2	72.9
Brain & Nervous System: ^e	3.9	4.6	3.5	2.5	3.1	2.0	38.0	33.8	42.4
Brain	3.6	4.2	3.1	-	-	-	33.7	30.0	37.8
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	72.7	69.5	75.3
Endocrine System:	7.4	4.1	10.3	0.8	0.7	0.9	90.9	83.5	93.0
Thyroid	6.5	3.2	9.3	0.5	0.4	0.6	94.9	90.9	95.7
Other endocrine & thymus	0.9	0.9	0.9	0.4	0.4	0.3	62.4	63.3	61.1
Lymphoma:	17.6	21.1	14.7	5.1	6.5	4.1	63.8	59.8	68.5
Hodgkin lymphoma	2.8	3.2	2.4	0.4	0.5	0.3	80.4	77.2	83.7
Non-Hodgkin lymphoma	14.8	17.9	12.3	4.7	6.1	3.8	59.9	55.8	64.8
Myeloma	11.9	14.5	10.2	6.6	8.2	5.6	39.1	38.3	39.9
Leukemia:	9.8	12.9	7.8	6.3	8.6	4.9	47.5	48.1	46.7
Lymphocytic:	4.2	6.1	2.9	1.8	2.8	1.2	64.2	63.1	65.9
Acute lymphocytic	1.0	1.2	0.8	0.3	0.4	0.2	62.0	60.5	64.1
Chronic lymphocytic	3.0	4.6	2.0	1.4	2.2	0.9	65.2	63.5	67.5
Other lymphocytic	0.2	0.4	0.1	0.1	0.2	0.1	62.2	68.0	48.7
Myeloid & Monocytic:	4.8	5.8	4.3	2.8	3.4	2.4	35.7	35.9	35.4
Acute myeloid	3.1	3.4	2.8	2.2	2.7	1.9	24.4	24.3	24.4
Chronic myeloid	1.5	1.9	1.2	0.4	0.5	0.3	58.3	58.3	58.0
Acute monocytic	0.2	0.2	0.1	0.0	-	-	17.7	20.8	0.0
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.2	0.1	40.8	32.2	46.9
Other leukemia:	0.8	1.0	0.6	1.7	2.4	1.4	26.2	27.4	24.6
Other acute leukemia	0.2	0.3	0.2	0.6	0.8	0.4	22.5	26.3	17.7
Aleukemic, subleukemic & NOS	0.5	0.7	0.4	1.2	1.6	0.9	28.3	27.8	28.5
Kaposi Sarcoma ^f	1.2	2.4	0.2	-	-	-	50.4	51.1	40.3
Mesothelioma ^f	0.7	1.2	0.3	-	-	-	12.8	11.8	15.3
Ill-defined & unspecified	11.1	12.6	10.0	16.2	21.6	12.8	11.3	12.1	10.4

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 17 areas. Based on follow-up of patients into 2008.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

SEER Incidence^a and US Death Rates,^b 2004-2008 5-Year Relative Survival,^c 2001-2007 All Cancer Combined, by Race and Sex





Figure 1.9

- ^a Incidence rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey) and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
- ^b Death rates are from the US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
- ^c Survival rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey).

Figure 1.11

5-Year Relative Survival (%) SEER Program, 2001-2007 Both Sexes, by Race and Cancer Site



Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey).

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 2.8
All Cancer Sites (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	39	-	-	27	-	-
1970-1973 ^a	-	-	-	43	-	-	31	-	-
1975-1977 ^b	49.1	41.9	56.0	50.0	42.9	56.7	39.2	32.8	46.3
1978-1980 ^b	49.2	43.3	55.1	50.1	44.5	55.7	39.0	33.4	45.7
1981-1983 ^b	50.4	45.4	55.3	51.5	46.8	56.1	39.0	34.3	44.6
1984-1986 ^b	52.5	47.3	57.7	53.8	48.8	58.7	40.2	35.6	45.5
1987-1989 ^b	55.5	51.3	59.8	56.8	53.0	60.8	43.1	39.0	47.8
1990-1992 ^b	60.1	59.3	61.0	61.5	61.0	62.2	47.9	47.7	48.3
1993-1995 ^b	61.4	61.0	61.9	62.5	62.1	63.0	52.7	54.4	50.6
1996-2000 ^b	64.3	64.2	64.5	65.4	65.4	65.5	56.0	58.7	52.9
2001-2007 ^b	67.4 ^e	68.1 ^e	66.5 ^e	68.6 ^e	69.3 ^e	67.8 ^e	59.4 ^e	63.2 ^e	55.1 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	65.9	66.6	65.2	66.5	67.0	66.0	58.6	61.9	54.9
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	79.7	74.7	82.9	81.3	76.8	84.4	66.9	59.5	71.4
Ages 45-54	72.0	66.1	76.8	73.6	67.6	78.5	59.9	58.0	61.9
Ages 55-64	69.1	69.0	69.1	70.0	69.7	70.4	61.6	65.2	55.8
Ages 65-74	64.5	68.0	59.4	65.0	68.2	60.5	58.7	65.6	48.3
Ages 75+	52.4	57.3	47.7	53.1	57.5	49.0	42.3	49.9	35.5
Ages <65	72.3	69.2	75.4	73.6	70.4	76.7	62.1	62.1	62.2
Ages 65+	58.4	63.1	52.9	58.9	63.2	53.9	51.8	60.0	42.0

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.
^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.
^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).
^e The standard error is between 5 and 10 percentage points.
^f The standard error is greater than 10 percentage points.
^g -
- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 3.8
Cancer of the Brain and Other Nervous System (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	18	16	21	19	17	21
1970-1973 ^a	-	-	-	20	18	22	19	19	19
1975-1977 ^b	22.4	20.7	24.7	21.8	20.2	24.0	25.4	19.6	34.7 ^f
1978-1980 ^b	23.6	22.4	25.3	23.1	21.9	24.6	28.2	28.8	27.5
1981-1983 ^b	24.1	23.0	25.4	23.3	22.4	24.4	30.8	31.7	29.2 ^f
1984-1986 ^b	27.0	25.8	28.5	26.3	25.0	27.8	30.9	32.8	28.3
1987-1989 ^b	28.9	27.4	30.9	28.3	26.4	30.7	31.3	33.5	28.8
1990-1992 ^b	30.2	30.5	29.8	29.2	29.4	29.0	40.0	41.6	38.1
1993-1995 ^b	32.2	32.8	31.5	31.0	31.3	30.5	41.2	45.7	36.3
1996-2000 ^b	31.9	30.5	33.7	31.1	29.9	32.6	36.3	33.3	39.9
2001-2007 ^b	34.8 ^e	33.4 ^e	36.5 ^e	33.7 ^e	32.9 ^e	34.8 ^e	39.8 ^e	35.2 ^e	44.2
5-Year Period Survival (Percent) ^{cd}									
2007	34.0	32.7	35.6	32.8	31.9	33.9	40.8	37.3	44.3
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	29,537	16,390	13,147	25,862	14,443	11,419	1,851	948	903
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	74	75	73	75	76	73	73	72	73
Regional	16	16	16	16	16	16	15	16	15
Distant	2	2	2	2	2	2	3	4	3
Unstaged	7	7	8	7	6	8	9	9	9
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	65.1	62.4	68.5	65.8	63.3	69.1	59.8	54.4	65.6
Ages 45-54	31.5	28.2	36.4	30.6	27.3	35.4	32.9	26.4	39.2
Ages 55-64	16.0	13.6	19.6	15.4	12.9	19.1	19.4	16.4	23.0
Ages 65-74	8.8	7.5	10.5	8.6	7.5	10.0	9.4	8.1	10.6
Ages 75+	4.3	3.5	4.9	4.2	3.5	4.6	8.4	6.0	9.7
Ages <65	44.9	41.5	49.6	44.3	41.0	48.9	46.2	40.4	52.7
Ages 65+	6.6	5.7	7.4	6.4	5.7	7.1	9.3	7.3	10.6
Stage:									
All Stages	33.4	31.8	35.4	32.5	31.2	34.2	38.0	33.8	42.4
Localized	36.2	34.2	38.8	35.3	33.5	37.6	40.8	37.0	44.7
Regional	21.3	21.0	21.7	20.0	20.1	19.8	28.8	23.8	33.7
Distant	36.8	36.0	37.6	37.8	37.4	38.2	33.9 ^f	31.2 ^f	38.5 ^f
Unstaged	30.4	29.1	31.7	29.6	28.4	30.6	30.9	23.8	38.7 ^f

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^e The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 4.14
Cancer of the Female Breast (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	63	-	-	46	-	-
1970-1973 ^a	-	-	-	68	-	-	51	-	-
1975-1977 ^b	75.1	76.7	74.6	75.9	77.9	75.2	62.2	62.4	62.1
1978-1980 ^b	74.6	75.6	74.3	75.3	76.3	75.0	63.4	67.2	61.5
1981-1983 ^b	76.4	77.5	76.0	77.3	78.7	77.0	63.8	65.4	63.0
1984-1986 ^b	79.2	77.9	79.6	80.2	79.7	80.4	65.2	64.0	65.9
1987-1989 ^b	84.2	81.5	85.2	85.3	82.9	86.1	71.3	69.6	72.3
1990-1992 ^b	85.4	83.4	86.1	86.6	85.2	87.1	71.7	70.4	72.5
1993-1995 ^b	86.5	84.3	87.3	87.8	86.3	88.4	72.7	70.2	74.1
1996-2000 ^b	89.1	87.4	89.7	90.2	89.1	90.5	77.5	75.7	78.6
2001-2007 ^b	90.0 ^e	89.2 ^e	90.3 ^e	91.4 ^e	91.0 ^e	91.6 ^e	77.4 ^e	76.8 ^e	77.7 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	89.2	88.8	89.4	90.5	90.3	90.5	77.7	77.4	77.9
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	292,714	73,750	218,964	241,734	56,867	184,867	26,966	8,735	18,231
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	60	53	63	61	54	63	51	47	53
Regional	33	41	30	32	41	30	38	44	35
Distant	5	4	5	5	4	5	8	7	9
Unstaged	2	1	2	2	1	2	2	2	3
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	86.9	-	-	88.3	-	-	76.0	-	-
Ages 45-54	89.8	-	-	91.2	-	-	78.2	-	-
Ages 55-64	90.1	-	-	91.2	-	-	78.9	-	-
Ages 65-74	90.5	-	-	91.5	-	-	80.0	-	-
Ages 75+	87.2	-	-	88.9	-	-	68.8	-	-
Ages <65	89.2	-	-	90.6	-	-	77.8	-	-
Ages 65+	88.9	-	-	90.2	-	-	75.2	-	-
Stage:									
All Stages	89.1	88.4	89.3	90.4	89.9	90.5	77.0	77.0	77.0
Localized	98.6	96.2	99.3	99.3	96.7	100.0	92.6	91.3	93.1
Regional	83.8	84.6	83.4	85.2	86.3	84.7	72.0	72.8	71.6
Distant	23.3	30.6	21.3	24.7	34.7	22.4	14.8	15.7	14.4
Unstaged	52.4	71.9	47.5	52.0	74.9	47.0	45.2	50.9	43.5
<i>In Situ</i> ^h	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.3	100.0

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^e The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

^h *In situ* cases are not included in the All Stages group.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 5.8
Cancer of the Cervix Uteri (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	58	-	-	47	-	-
1970-1973 ^a	-	-	-	64	-	-	61	-	-
1975-1977 ^b	69.1	82.5	57.9	69.8	83.9	58.2	64.5	75.5	54.9
1978-1980 ^b	67.5	78.5	57.8	68.2	79.8	58.4	60.9	70.4	51.9
1981-1983 ^b	67.1	79.5	55.1	67.9	80.7	55.3	59.6	73.6	47.1
1984-1986 ^b	67.2	78.0	55.3	69.0	79.7	56.5	57.6	68.0	47.7
1987-1989 ^b	70.1	79.6	58.3	72.5	82.6	58.6	57.3	63.3	52.3
1990-1992 ^b	69.6	79.0	57.0	70.9	81.2	56.6	57.9	63.4	51.0
1993-1995 ^b	72.6	81.8	59.8	74.2	83.5	60.2	63.0	70.9	53.4
1996-2000 ^b	72.9	82.3	59.2	73.8	83.8	57.9	66.6	71.0	61.0
2001-2007 ^b	68.9	80.0 ^e	54.1 ^e	70.3	82.2	53.5 ^e	60.9	71.3	49.4
5-Year Period Survival (Percent) ^{cd}									
2007	67.9	77.3	55.9	69.2	78.6	56.4	57.8	67.7	46.7
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	20,970	11,727	9,243	15,987	9,172	6,815	2,683	1,386	1,297
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	48	60	34	49	61	34	42	51	31
Regional	36	29	44	35	28	45	40	35	45
Distant	12	8	16	12	8	17	13	9	18
Unstaged	4	3	5	4	3	5	6	5	6
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	80.2	-	-	81.8	-	-	69.9	-	-
Ages 45-54	67.8	-	-	69.1	-	-	57.3	-	-
Ages 55-64	60.7	-	-	60.6	-	-	53.7	-	-
Ages 65-74	55.3	-	-	55.6	-	-	44.8	-	-
Ages 75+	36.8	-	-	36.5	-	-	34.3	-	-
Ages <65	73.0	-	-	74.5	-	-	62.7	-	-
Ages 65+	47.3	-	-	47.4	-	-	40.4	-	-
Stage:									
All Stages	68.6	78.1	56.1	70.0	79.7	56.6	58.4	67.8	47.9
Localized	90.9	93.4	85.3	92.1	94.2	86.7	83.1	87.6	74.4
Regional	56.9	62.8	51.8	58.0	64.7	52.0	48.6	52.5	45.1
Distant	16.5	21.3	13.4	17.5	23.5	13.4	11.7	10.1	12.6
Unstaged	53.7	77.0	34.5	53.0	77.0	33.6	51.9	72.6 ^f	33.5 ^f

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 6.12
Cancer of the Colon and Rectum (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	50.0	49.2	50.8	50.2	49.6	50.9	45.1	43.4	46.4
1978-1980 ^b	51.4	50.5	52.3	51.8	50.8	52.6	45.6	43.6	47.0
1981-1983 ^b	54.3	54.0	54.5	54.7	54.7	54.6	46.6	42.8	49.7
1984-1986 ^b	57.9	57.9	57.8	58.6	58.7	58.4	48.4	47.5	49.2
1987-1989 ^b	59.8	60.1	59.5	60.3	60.8	59.7	52.4	50.1	54.5
1990-1992 ^b	61.4	61.3	61.6	62.2	62.0	62.4	53.0	54.6	51.5
1993-1995 ^b	60.1	59.9	60.4	60.8	60.5	61.0	52.1	51.3	52.7
1996-2000 ^b	63.6	63.9	63.3	64.5	64.7	64.4	53.8	54.6	53.1
2001-2007 ^b	66.0 ^e	66.4 ^e	65.6 ^e	67.1 ^e	67.9 ^e	66.3 ^e	56.3 ^e	54.7 ^e	57.6 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	65.1	65.4	64.7	65.7	66.2	65.1	57.5	56.3	58.5
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	200,444	101,559	98,885	162,053	82,703	79,350	20,841	9,687	11,154
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	39	40	38	39	40	38	35	35	36
Regional	37	36	37	37	36	37	35	35	35
Distant	20	20	20	19	19	19	24	25	24
Unstaged	5	4	5	5	4	5	5	5	6
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	67.3	66.1	68.6	68.8	66.8	71.1	58.9	58.3	59.4
Ages 45-54	69.5	68.4	70.9	70.3	69.4	71.6	60.5	57.4	63.4
Ages 55-64	67.8	67.2	68.8	68.5	68.0	69.3	60.3	58.5	62.2
Ages 65-74	66.4	66.1	66.8	67.0	66.9	67.1	59.0	56.9	60.8
Ages 75+	58.4	59.0	58.0	59.7	60.5	59.2	44.7	43.2	45.5
Ages <65	68.3	67.4	69.5	69.2	68.3	70.4	60.1	58.1	62.2
Ages 65+	61.7	62.4	61.1	62.5	63.4	61.8	51.8	51.1	52.3
Stage:									
All Stages	64.3	64.6	64.0	65.0	65.5	64.5	56.0	55.0	56.9
Localized	90.1	90.1	90.0	90.6	90.7	90.4	85.1	83.2	86.6
Regional	69.2	69.1	69.4	69.7	69.7	69.8	63.5	62.8	64.1
Distant	11.7	11.1	12.3	12.1	11.5	12.8	8.5	7.8	9.0
Unstaged	33.3	36.8	30.3	31.4	35.0	28.3	33.7	34.9	32.6

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 6.13
Cancer of the Colon (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	43	42	44	34	32	35
1970-1973 ^a	-	-	-	49	47	50	37	36	38
1975-1977 ^b	50.9	50.3	51.3	51.1	50.7	51.4	45.3	43.9	46.1
1978-1980 ^b	52.5	51.5	53.4	52.6	51.6	53.5	49.0	47.5	50.0
1981-1983 ^b	55.4	55.8	55.0	55.7	56.4	55.0	48.7	44.9	51.7
1984-1986 ^b	58.5	59.0	58.0	59.2	59.8	58.6	49.2	48.8	49.5
1987-1989 ^b	60.4	61.0	59.9	60.9	61.7	60.1	52.5	50.8	53.8
1990-1992 ^b	62.2	62.5	61.9	63.0	63.3	62.7	53.5	55.0	52.3
1993-1995 ^b	60.1	60.3	59.9	60.8	61.0	60.6	51.5	51.0	51.8
1996-2000 ^b	63.3	64.0	62.7	64.4	64.9	63.9	53.5	54.8	52.4
2001-2007 ^b	65.2 ^e	65.6 ^e	64.9 ^e	66.5 ^e	67.2 ^e	65.8 ^e	54.8 ^e	53.0 ^e	56.1 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	64.4	64.9	64.0	65.1	65.7	64.5	56.8	56.0	57.5
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	141,931	68,502	73,429	114,873	55,881	58,992	15,617	7,022	8,595
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	37	38	36	37	38	37	33	33	33
Regional	38	38	39	38	38	39	37	37	37
Distant	21	21	21	20	20	20	26	26	25
Unstaged	4	4	5	4	4	5	5	4	5
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	65.9	65.4	66.4	67.9	66.0	69.9	58.4	60.3	56.6
Ages 45-54	66.8	65.9	68.0	67.8	67.1	68.7	58.7	55.9	61.1
Ages 55-64	66.4	66.1	66.9	67.4	67.2	67.6	58.4	57.2	59.8
Ages 65-74	66.4	66.2	66.6	67.0	67.1	66.9	59.1	56.8	61.1
Ages 75+	59.6	60.2	59.1	60.9	61.7	60.3	45.8	44.6	46.4
Ages <65	66.5	65.9	67.2	67.6	67.0	68.3	58.5	57.2	59.8
Ages 65+	62.2	62.9	61.6	63.1	64.0	62.3	52.3	51.5	52.9
Stage:									
All Stages	63.6	64.0	63.2	64.5	65.1	64.0	55.2	54.4	55.8
Localized	91.1	91.4	90.8	91.7	92.2	91.1	86.1	84.0	87.6
Regional	69.8	69.6	70.0	70.3	70.2	70.4	64.7	64.2	65.0
Distant	11.4	10.8	11.9	11.9	11.2	12.4	8.3	7.7	8.8
Unstaged	27.4	31.3	24.5	25.9	29.7	23.1	27.0	30.6	24.4

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 6.14
Cancer of the Rectum (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	38	36	41	27	28	27
1970-1973 ^a	-	-	-	45	43	48	30	20	40
1975-1977 ^b	48.3	47.2	49.6	48.4	47.5	49.5	44.6	41.8	46.9
1978-1980 ^b	49.1	48.6	49.6	49.9	49.5	50.3	34.9	34.0	35.6
1981-1983 ^b	51.7	50.5	53.1	52.4	51.3	53.6	39.8	37.3	42.4
1984-1986 ^b	56.5	55.9	57.3	57.3	56.7	57.9	45.8	43.5	48.0
1987-1989 ^b	58.3	58.1	58.5	58.8	59.1	58.5	52.3	47.7	57.1
1990-1992 ^b	59.5	58.7	60.6	60.2	59.3	61.4	51.3	53.5	48.7
1993-1995 ^b	60.4	59.2	61.8	60.8	59.7	62.2	54.0	51.8	56.5
1996-2000 ^b	64.4	63.8	65.1	65.0	64.3	65.7	54.8	54.2	55.3
2001-2007 ^b	68.0 ^e	68.2 ^e	67.6 ^e	68.7 ^e	69.5 ^e	67.8 ^e	60.9 ^e	59.0 ^e	62.7 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	66.7	66.6	66.8	67.0	67.1	66.8	59.3	56.9	61.6
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	58,513	33,057	25,456	47,180	26,822	20,358	5,224	2,665	2,559
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	44	44	44	44	44	44	43	41	45
Regional	33	34	32	33	34	33	29	31	28
Distant	17	18	17	17	17	17	20	21	18
Unstaged	6	5	7	5	5	6	8	7	8
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	69.4	67.0	72.2	70.2	68.0	73.0	59.6	54.7	65.1
Ages 45-54	73.6	71.8	76.1	74.1	72.5	76.5	64.2	60.3	68.7
Ages 55-64	70.6	69.2	73.0	70.7	69.3	73.1	65.4	62.1	69.5
Ages 65-74	66.5	65.8	67.5	67.0	66.5	67.9	58.4	57.3	59.2
Ages 75+	54.6	55.4	53.8	55.6	56.8	54.6	39.9	37.2	41.0
Ages <65	71.5	69.8	74.0	71.9	70.3	74.3	64.0	60.1	68.5
Ages 65+	60.3	61.1	59.4	61.0	62.0	59.8	50.0	49.8	49.7
Stage:									
All Stages	66.0	65.8	66.2	66.3	66.3	66.3	58.5	56.4	60.4
Localized	88.1	87.9	88.4	88.4	88.2	88.6	83.0	81.6	84.2
Regional	67.7	68.0	67.3	68.3	68.6	67.8	59.2	58.4	59.8
Distant	12.7	11.9	13.7	12.9	12.2	13.8	8.9	8.2	9.7
Unstaged	43.9	45.1	42.7	41.7	43.4	39.9	45.7	41.6	48.9

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 7.8
Cancer of the Corpus and Uterus, NOS (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	73	-	-	31	-	-
1970-1973 ^a	-	-	-	81	-	-	44	-	-
1975-1977 ^b	87.0	92.7	86.3	88.1	93.3	87.5	60.3	84.4 ^f	55.8
1978-1980 ^b	82.6	91.7	81.4	83.8	93.1	82.8	55.0	82.3 ^f	49.7
1981-1983 ^b	80.8	91.2	79.5	82.2	92.3	81.1	50.9	82.7 ^f	46.0
1984-1986 ^b	82.6	93.6	81.2	84.1	93.9	82.9	56.3	83.6 ^f	52.7
1987-1989 ^b	82.5	90.2	81.4	84.1	91.0	83.2	57.0	84.6 ^f	53.1
1990-1992 ^b	83.7	90.1	82.7	85.8	92.3	84.9	53.9	72.5 ^f	50.2
1993-1995 ^b	83.2	90.1	82.0	84.9	91.6	83.9	58.6	81.7	54.0
1996-2000 ^b	84.2	89.9	83.1	85.8	90.5	85.1	61.6	79.2	57.6
2001-2007 ^b	83.2 ^e	88.7 ^e	82.2 ^e	85.4 ^e	91.3	84.5 ^e	60.8	72.6	57.7
5-Year Period Survival (Percent) ^{cd}									
2007	82.2	89.1	80.8	84.0	90.0	82.9	61.3	79.8	57.6
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	56,876	9,091	47,785	47,628	7,014	40,614	4,584	749	3,835
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	68	73	68	70	74	69	53	63	51
Regional	20	17	20	19	17	19	25	17	27
Distant	8	7	9	8	6	8	16	14	16
Unstaged	4	4	4	4	3	4	6	6	6
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	89.7	-	-	90.7	-	-	81.5	-	-
Ages 45-54	87.8	-	-	89.1	-	-	68.7	-	-
Ages 55-64	85.5	-	-	87.5	-	-	64.2	-	-
Ages 65-74	78.3	-	-	81.5	-	-	50.8	-	-
Ages 75+	69.2	-	-	71.5	-	-	44.7	-	-
Ages <65	86.9	-	-	88.5	-	-	68.8	-	-
Ages 65+	74.3	-	-	76.9	-	-	48.7	-	-
Stage:									
All Stages	81.8	89.0	80.4	83.7	90.1	82.6	60.2	78.3	56.4
Localized	95.8	96.6	95.6	96.5	96.6	96.5	85.0	93.9	82.7
Regional	67.0	82.4	64.3	69.1	83.6	66.9	45.4	73.0	41.5
Distant	15.9	27.5	14.1	16.9	30.7	15.0	9.7	17.9	8.1
Unstaged	50.1	84.4	43.7	49.9	84.5	44.4	35.8	73.3 ^f	27.8

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 8.8
Cancer of the Esophagus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	4	4	6	1	0	2
1970-1973 ^a	-	-	-	4	4	4	4	4	3
1975-1977 ^b	5.0	3.9	7.5	5.5	4.8	7.0	3.2	1.6	7.7
1978-1980 ^b	5.0	4.8	5.6	5.3	5.3	5.2	4.3	3.4	6.9
1981-1983 ^b	6.6	6.0	8.2	7.3	6.5	9.0	4.3	3.7	6.5
1984-1986 ^b	9.6	8.6	12.0	10.4	9.2	12.9	8.7	8.2	9.9
1987-1989 ^b	9.5	9.4	9.7	10.7	11.1	9.6	6.6	5.3	10.2
1990-1992 ^b	12.3	11.9	13.4	13.1	12.5	14.9	9.2	9.4	8.4
1993-1995 ^b	12.2	12.3	11.7	13.5	13.7	12.8	7.5	7.8	6.9
1996-2000 ^b	15.4	14.9	17.0	16.3	15.9	17.7	11.1	9.6	14.1
2001-2007 ^b	18.5 ^e	18.4 ^e	18.8 ^e	19.6 ^e	19.7 ^e	19.4 ^e	12.8 ^e	10.6 ^e	17.1 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	17.6	17.9	16.6	18.4	18.8	17.1	12.0	11.0	14.3
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	18,310	14,102	4,208	15,301	11,936	3,365	1,976	1,390	586
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	22	22	25	23	22	26	20	18	23
Regional	32	33	29	32	32	29	34	35	33
Distant	32	34	27	32	34	26	32	33	28
Unstaged	14	12	19	13	12	19	14	13	17
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	18.9	18.9	18.9	20.4	20.0	22.2	9.6	10.6 ^f	6.0 ^f
Ages 45-54	19.0	18.2	23.5	20.3	19.3	26.4	13.0	10.6	18.7
Ages 55-64	19.6	19.1	22.0	20.9	20.5	23.6	11.1	11.0	10.3
Ages 65-74	17.5	17.3	18.3	18.4	18.3	18.5	11.8	10.2	15.7
Ages 75+	12.1	12.2	11.7	12.5	12.5	12.3	8.3	9.0	6.3
Ages <65	19.4	18.8	22.3	20.7	20.1	24.4	11.8	10.9	14.3
Ages 65+	14.8	15.0	14.2	15.4	15.7	14.6	10.5	9.8	11.6
Stage:									
All Stages	16.8	16.8	16.8	17.7	17.8	17.4	11.2	10.5	12.9
Localized	37.3	39.6	30.4	39.6	42.0	32.1	21.3	22.9	18.2
Regional	18.4	18.1	19.4	19.2	19.0	20.2	12.8	11.2	16.1
Distant	3.1	2.9	4.1	3.1	3.0	3.9	3.3	2.8	4.9
Unstaged	11.4	11.0	12.3	11.3	11.3	11.0	10.6	9.7	12.6

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 9.8
Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	40	34	48	-	-	-
1970-1973 ^a	-	-	-	67	66	69	-	-	-
1975-1977 ^b	72.0	70.3	74.3	72.3	70.5	74.5	70.2	68.6 ^f	73.3 ^f
1978-1980 ^b	71.7	70.3	73.5	71.8	69.8	74.3	70.6	74.8 ^f	63.1 ^f
1981-1983 ^b	74.2	72.9	75.9	74.6	73.8	75.6	71.6	69.2 ^f	76.0 ^f
1984-1986 ^b	78.4	76.6	80.7	78.9	77.0	81.2	74.7	75.7 ^f	72.2 ^f
1987-1989 ^b	79.3	76.7	82.6	79.8	76.9	83.5	72.2	71.8 ^f	72.7 ^f
1990-1992 ^b	81.7	79.2	84.6	82.8	81.1	84.9	73.6	63.8	84.1
1993-1995 ^b	81.7	79.1	84.7	82.1	79.9	84.7	78.2	73.9	82.8
1996-2000 ^b	85.1	83.6	86.8	85.5	83.9	87.4	81.7	80.4	83.3
2001-2007 ^b	86.3 ^e	85.5 ^e	87.3 ^e	87.5 ^e	87.0 ^e	88.1 ^e	80.9 ^e	77.2	84.4
5-Year Period Survival (Percent) ^{cd}									
2007	83.6	82.8	84.4	83.6	82.8	84.5	81.2	79.7	82.6
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	13,651	7,444	6,207	11,427	6,230	5,197	1,425	760	665
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	18	19	17	18	19	17	21	21	20
Regional	41	36	46	41	37	47	33	29	38
Distant	36	40	32	36	39	31	42	46	38
Unstaged	5	5	5	5	5	5	4	4	4
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	92.8	91.9	93.9	93.6	92.9	94.4	86.4	82.9	89.7
Ages 45-54	83.0	80.2	87.4	84.1	81.2	88.5	74.2	69.9	81.6 ^f
Ages 55-64	73.5	70.5	78.1	74.5	71.7	78.9	64.2 ^f	58.0 ^f	71.4 ^f
Ages 65-74	57.6	55.6	59.9	57.8	55.3	60.8	56.5 ^f	59.6 ^g	52.7 ^g
Ages 75+	37.9	38.4	37.0	39.2	39.2	38.8	23.6 ^g	-	-
Ages <65	89.5	87.7	91.8	90.3	88.6	92.4	82.6	78.4	87.2
Ages 65+	48.2	48.6	47.9	48.8	48.7	48.9	48.0 ^f	55.4 ^g	40.9 ^f
Stage:									
All Stages	83.9	82.8	85.2	84.3	83.3	85.4	80.4	77.2	83.7
Localized	89.8	90.3	89.1	89.9	90.3	89.3	90.3	91.6	88.1
Regional	90.4	89.7	91.0	90.7	90.0	91.3	85.8	82.6	88.1
Distant	73.7	72.8	75.1	74.0	73.6	74.5	72.1	66.9	78.5
Unstaged	82.2	83.1	81.0	82.9	83.2	82.0	68.5 ^f	69.8 ^g	66.6 ^g

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).^e The standard error is between 5 and 10 percentage points.^f The standard error is greater than 10 percentage points.^g -
Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 10.6
Kaposi Sarcoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	82.2 ^f	82.0 ^f	-	81.6 ^f	80.2 ^f	-	-	-	-
1978-1980 ^b	78.1 ^f	79.1 ^f	73.1 ^g	77.4 ^f	77.5 ^f	72.9 ^g	-	-	-
1981-1983 ^b	35.9	33.2	70.8 ^g	34.3	31.6	68.7 ^g	-	-	-
1984-1986 ^b	12.8	11.5	70.9 ^g	12.5	11.2	70.7 ^g	16.8	15.7	-
1987-1989 ^b	9.9	9.2	69.0 ^g	9.4	8.8	72.3 ^g	12.0	10.8	-
1990-1992 ^b	9.4	8.7	52.6 ^f	9.0	8.4	52.3 ^f	11.6	10.6	-
1993-1995 ^b	21.7	21.0	52.2 ^f	22.3	21.5	60.0 ^g	16.3	15.4	-
1996-2000 ^b	53.0	52.2	68.5 ^f	58.0	56.7	83.6 ^g	39.8	39.6	-
2001-2007 ^b	66.9 ^e	66.3 ^e	69.7 ^f	76.1 ^e	74.6	79.3 ^f	47.7	48.7	-
5-Year Period Survival (Percent) ^{cd}									
2007	68.0	67.5	74.1	73.4	72.5	80.3	48.8	49.1	-
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	61.7	62.1	41.4 ^f	66.6	66.6	-	48.4	49.5	25.4 ^g
Ages 45-54	63.4	64.4	-	66.7	67.4	-	48.5 ^f	50.5 ^f	-
Ages 55-64	76.0	76.8	-	78.3	78.3	-	46.7 ^g	48.0 ^g	-
Ages 65-74	83.9	86.3	68.8 ^g	82.4	84.5	68.1 ^g	-	-	-
Ages 75+	90.1	94.2 ^f	79.6 ^f	91.6	94.9 ^f	82.3 ^f	-	-	-
Ages <65	63.3	63.9	41.4 ^f	67.8	67.9	60.4 ^g	48.4	49.7	26.6 ^f
Ages 65+	88.4	92.0	78.4 ^f	88.7	92.1	80.3 ^f	87.3 ^f	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.
^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.
^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).
^e The standard error is between 5 and 10 percentage points.
^f The standard error is greater than 10 percentage points.
^g -
Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 11.8
Cancer of the Kidney and Renal Pelvis (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	37	36	39	38	38	37
1970-1973 ^a	-	-	-	46	44	50	44	40	49
1975-1977 ^b	50.2	50.3	50.0	49.9	50.2	49.4	49.3	47.9	51.5 ^f
1978-1980 ^b	53.0	52.7	53.4	52.7	52.9	52.2	57.0	51.9	63.4 ^f
1981-1983 ^b	50.2	51.2	48.5	50.1	51.3	47.9	50.7	50.3	51.2
1984-1986 ^b	54.8	55.3	53.8	54.9	55.7	53.7	52.9	49.7	57.8
1987-1989 ^b	56.7	57.1	56.1	57.3	58.1	56.1	54.8	52.7	57.2
1990-1992 ^b	60.3	60.6	59.8	60.8	61.2	60.0	57.2	55.6	58.9
1993-1995 ^b	61.5	61.7	61.3	62.0	62.8	60.8	57.5	54.3	62.0
1996-2000 ^b	63.3	62.7	64.1	63.0	62.8	63.3	65.6	64.2	66.7
2001-2007 ^b	70.9 ^e	70.7 ^e	71.0 ^e	71.0 ^e	70.8 ^e	71.2 ^e	68.4 ^e	68.0 ^e	68.7 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	71.5	71.7	71.3	71.9	72.2	71.6	68.4	68.1	68.8
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	55,307	33,945	21,362	46,494	28,609	17,885	5,338	3,187	2,151
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	61	60	63	60	59	63	65	64	68
Regional	17	18	16	18	18	16	13	13	12
Distant	18	19	16	18	19	16	18	19	16
Unstaged	4	4	5	4	4	5	4	4	4
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	83.3	81.6	85.6	84.6	83.0	87.0	73.0	69.4	77.7
Ages 45-54	76.6	74.7	80.4	77.0	74.8	81.3	72.1	71.0	74.3
Ages 55-64	71.4	70.3	73.4	71.9	70.7	74.2	67.0	67.0	66.9
Ages 65-74	67.8	67.5	68.2	67.8	67.2	68.7	66.5	69.3	62.9
Ages 75+	55.3	57.5	53.0	56.3	58.7	53.6	46.1	45.2	46.1
Ages <65	75.5	73.9	78.5	76.0	74.3	79.3	70.3	69.0	72.6
Ages 65+	61.9	63.1	60.2	62.2	63.4	60.6	58.3	61.1	55.4
Stage:									
All Stages	69.5	69.5	69.4	69.7	69.7	69.8	66.2	66.6	65.6
Localized	90.8	91.1	90.3	91.5	91.6	91.3	85.0	86.1	83.4
Regional	63.1	65.1	59.5	63.5	65.3	60.2	57.8	62.2	50.6
Distant	11.0	11.7	9.7	10.5	11.4	8.9	12.0	11.4	13.1
Unstaged	34.8	36.9	32.3	34.2	36.1	31.7	32.4	35.6 ^f	27.3 ^f

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^e The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 12.8
Cancer of the Larynx (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	53	54	46	-	-	-
1970-1973 ^a	-	-	-	62	63	56	-	-	-
1975-1977 ^b	66.3	67.0	62.5	67.0	67.8	62.2	58.5	57.5	63.4 ^f
1978-1980 ^b	65.4	65.6	64.1	66.3	66.5	64.8	56.9	57.2	55.8 ^f
1981-1983 ^b	68.2	68.4	67.1	69.6	69.8	68.5	56.5	57.3	52.8 ^f
1984-1986 ^b	65.4	66.0	62.2	67.3	67.9	63.9	52.7	52.9	51.1 ^f
1987-1989 ^b	65.8	66.9	61.5	67.2	68.8	61.1	56.1	54.3	61.4 ^f
1990-1992 ^b	66.0	66.9	62.6	67.9	68.6	64.7	53.5	54.1	51.3 ^f
1993-1995 ^b	63.7	65.4	56.5	65.3	67.2	57.4	53.0	54.3	47.4 ^f
1996-2000 ^b	64.6	66.2	58.9	66.8	68.3	61.1	51.0	52.6	46.5
2001-2007 ^b	62.7 ^e	62.8 ^e	62.1	64.9	65.0 ^e	64.7	51.9	52.8	48.3
5-Year Period Survival (Percent) ^{cd}									
2007	60.6	61.5	57.0	61.8	62.7	58.2	52.3	53.2	48.1
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	14,813	11,908	2,905	12,032	9,638	2,394	2,148	1,724	424
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	57	59	51	59	61	52	46	47	42
Regional	20	18	27	19	17	27	23	22	30
Distant	17	18	16	16	16	15	26	27	23
Unstaged	5	5	6	6	5	6	5	5	6
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	71.5	70.8	72.8	74.2	73.9	74.7	56.2 ^f	53.7 ^f	62.1 ^f
Ages 45-54	61.7	62.1	59.9	65.2	65.4	64.1	49.3	50.6	44.0 ^f
Ages 55-64	62.7	63.5	59.3	63.8	64.5	60.3	55.3	56.3	49.0 ^f
Ages 65-74	59.3	60.8	53.1	58.9	60.1	54.0	57.3	60.2	43.9 ^f
Ages 75+	55.9	57.5	49.4	57.2	58.9	50.3	42.7 ^f	42.0 ^f	44.9 ^g
Ages <65	63.2	63.6	61.4	65.2	65.6	63.5	53.0	54.0	48.8
Ages 65+	58.0	59.6	51.7	58.1	59.6	52.6	53.8	56.0	43.9 ^f
Stage:									
All Stages	60.8	61.8	56.7	61.8	62.8	58.0	53.2	54.7	47.1
Localized	76.7	77.5	72.6	76.8	77.7	73.0	72.8	74.2	66.2
Regional	41.3	41.5	40.9	41.3	40.8	42.5	40.8	43.6	31.7 ^f
Distant	33.4	32.6	36.8	34.4	33.5	38.0	30.8	30.5	32.8 ^f
Unstaged	50.4	51.8	45.1	49.3	50.8	42.9 ^f	47.0 ^f	46.1 ^f	-

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 13.14
Leukemia

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	14	-	-	-	-	-
1970-1973 ^a	-	-	-	22	-	-	-	-	-
1975-1977 ^b	34.4	33.3	35.7	34.8	33.8	36.0	33.1	30.0	36.5
1978-1980 ^b	36.3	35.2	37.7	36.9	35.9	38.2	28.7	28.2	29.3
1981-1983 ^b	37.6	37.3	37.9	38.4	38.2	38.6	33.9	33.4	34.3
1984-1986 ^b	40.7	40.2	41.2	41.8	41.5	42.3	32.9	31.9	34.1
1987-1989 ^b	43.0	44.3	41.4	44.0	45.7	41.8	35.5	33.7	37.7
1990-1992 ^b	45.2	44.7	46.0	46.4	46.3	46.6	36.0	31.0	41.4
1993-1995 ^b	47.3	48.2	46.1	48.3	49.2	47.0	41.1	41.0	41.1
1996-2000 ^b	47.9	48.5	47.0	49.0	49.4	48.5	38.3	38.9	37.5
2001-2007 ^b	56.5 ^e	56.7 ^e	56.1 ^e	57.1 ^e	57.2 ^e	56.8 ^e	50.3 ^e	52.0 ^e	48.3
5-Year Period Survival (Percent) ^{cd}									
2007	55.2	55.6	54.7	55.2	55.4	55.0	49.5	51.3	47.6
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	70.1	68.9	71.7	71.1	70.1	72.5	60.4	57.0	64.9
Ages 45-54	63.2	64.7	60.8	64.2	65.6	62.0	52.9	54.6	50.4
Ages 55-64	59.9	59.7	60.2	60.7	59.9	62.0	46.8	50.1	41.7
Ages 65-74	50.9	50.0	52.3	51.7	50.4	53.6	43.4	42.5	44.2
Ages 75+	34.3	33.1	35.4	34.5	33.4	35.7	25.5	22.4	27.1
Ages <65	65.4	65.0	66.1	66.3	65.7	67.1	55.1	54.6	55.8
Ages 65+	41.2	40.9	41.5	41.5	41.1	42.0	34.6	34.1	34.7

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).^e The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).^f The standard error is between 5 and 10 percentage points.^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 13.15
Lymphocytic Leukemia

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>Acute Lymphocytic Leukemia</u>									
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	40.9	37.2	46.0	41.2	37.7	46.1	33.5 ^e	-	-
1978-1980 ^a	49.0	45.5	54.3	49.3	45.9	54.3	31.4 ^e	30.9 ^e	-
1981-1983 ^a	50.5	47.2	55.0	51.3	48.1	55.7	42.3 ^e	36.3 ^e	48.4 ^e
1984-1986 ^a	52.3	49.1	56.7	53.1	49.3	58.6	36.0 ^e	43.5 ^e	27.3 ^e
1987-1989 ^a	54.4	53.8	55.1	55.0	55.0	55.0	44.7 ^e	42.0 ^e	47.1 ^e
1990-1992 ^a	58.0	54.5	63.1	57.7	55.0	61.9	57.1 ^e	50.4 ^e	63.3 ^e
1993-1995 ^a	60.0	57.8	63.2	59.6	57.9	62.1	52.6 ^e	44.6 ^e	63.8 ^e
1996-2000 ^b	64.8	64.2	65.5	65.8	65.0	66.7	56.1	55.2 ^e	57.3 ^e
2001-2007 ^a	66.6 ^d	65.0 ^d	68.8 ^d	66.9 ^d	65.0 ^d	69.7 ^d	61.5 ^d	62.7 ^e	60.5 ^e
5-Year Period Survival (Percent) ^{bc}									
2007	65.3	65.7	64.9	64.8	65.1	64.6	62.3	68.0	55.2
5-Year Relative Survival (Percent), 2001-2007 ^b									
Age at Diagnosis:									
Ages <45	75.4	73.1	78.6	75.7	73.5	78.8	71.8	67.4	78.4
Ages 45-54	26.7	28.1	24.8	25.1	25.6	24.4	24.5 ^e	-	-
Ages 55-64	19.9	19.9	19.5	20.3	20.2	19.9	-	-	-
Ages 65-74	10.8	10.6	10.8	11.0	11.1	10.8	-	-	-
Ages 75+	7.0	8.3	6.3	5.9	6.3	5.7	-	-	-
Ages <65	69.2	67.7	71.2	69.2	67.7	71.4	66.0	63.4	69.5
Ages 65+	9.1	9.4	8.6	8.6	8.9	8.2	0.0	-	-
<u>Chronic Lymphocytic Leukemia</u>									
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	67.4	65.0	70.5	68.2	65.7	71.4	56.5 ^e	55.2 ^e	58.1 ^e
1978-1980 ^a	68.3	65.2	72.4	68.9	65.6	73.3	57.9 ^e	58.5 ^e	57.1 ^e
1981-1983 ^a	66.3	65.8	67.1	66.8	66.6	67.3	57.4 ^e	55.0 ^e	60.4 ^e
1984-1986 ^a	72.6	71.5	74.2	73.0	71.8	74.5	68.0 ^e	66.0 ^e	68.5 ^e
1987-1989 ^a	73.1	73.1	73.0	74.1	74.2	73.9	59.5	58.5 ^e	60.8 ^e
1990-1992 ^a	74.2	72.1	77.1	75.4	73.4	78.1	52.6	44.6 ^e	60.9 ^e
1993-1995 ^a	77.1	76.9	77.2	78.0	77.8	78.3	63.9	63.5 ^e	64.0 ^e
1996-2000 ^b	74.8	73.8	76.3	75.7	74.7	77.1	57.1	52.0 ^e	62.6 ^e
2001-2007 ^a	80.8 ^d	79.9 ^d	82.0 ^d	81.0 ^d	80.0 ^d	82.6 ^d	72.4 ^d	71.4 ^d	73.4 ^e
5-Year Period Survival (Percent) ^{bc}									
2007	78.4	76.9	80.6	78.3	76.5	81.1	67.4	67.2	68.0
5-Year Relative Survival (Percent), 2001-2007 ^b									
Age at Diagnosis:									
Ages <45	90.7	88.6	94.5	93.5	91.6	97.1	64.5 ^e	-	-
Ages 45-54	90.8	89.8	92.6	91.5	90.5	93.2	76.6	76.3 ^e	76.7 ^e
Ages 55-64	86.1	83.6	91.3	86.8	84.1	92.0	68.9	67.9	71.6 ^e
Ages 65-74	82.4	79.7	86.4	82.7	79.6	87.7	72.4	72.7 ^e	71.9 ^e
Ages 75+	64.5	61.0	68.1	64.4	60.9	68.0	46.9	33.5 ^e	57.6 ^e
Ages <65	87.9	85.8	91.9	88.7	86.6	92.7	71.1	70.2	73.0 ^e
Ages 65+	72.4	70.1	75.3	72.4	69.9	75.5	60.6	56.3	64.7

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2008.

^b SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^c Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^d The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 13.16
Myeloid Leukemia

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>Acute Myeloid Leukemia</u>									
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	6.2	5.5	7.0	5.8	5.4	6.2	10.1	8.2	11.7
1978-1980 ^a	7.6	7.0	8.4	7.1	6.1	8.3	9.6	6.7	12.7
1981-1983 ^a	8.4	7.3	9.8	7.7	6.4	9.3	12.1	15.4 ^e	9.0
1984-1986 ^a	10.7	9.4	12.3	10.4	9.2	11.8	9.8	6.7	12.9
1987-1989 ^a	11.4	9.2	14.1	11.4	9.7	13.2	9.2	4.4	15.7 ^e
1990-1992 ^a	13.7	12.3	15.2	13.4	12.0	15.0	13.5	13.0	13.9
1993-1995 ^a	16.2	14.9	17.6	15.5	14.2	17.0	21.6	20.7 ^e	22.0
1996-2000 ^b	17.2	16.4	18.3	16.4	15.2	17.9	19.6	25.3	14.0
2001-2007 ^a	23.6 ^d	21.4 ^d	26.3 ^d	23.3 ^d	20.7 ^d	26.2 ^d	24.2 ^d	23.6 ^d	24.0
5-Year Period Survival (Percent) ^{bc}									
2007	24.2	22.5	26.2	23.7	22.1	25.8	24.6	23.4	25.5
5-Year Relative Survival (Percent), 2001-2007 ^b									
Age at Diagnosis:									
Ages <45	53.9	51.2	57.0	54.8	52.6	57.4	45.1	40.9	50.5
Ages 45-54	35.4	34.0	37.2	36.6	35.7	37.7	27.0	24.7 ^e	30.4 ^e
Ages 55-64	21.4	18.3	25.4	21.1	17.8	25.6	19.7	20.0	18.2
Ages 65-74	10.1	8.4	12.4	10.1	8.2	12.7	11.1	8.5	14.1
Ages 75+	1.8	1.9	1.5	1.7	2.0	1.3	1.9	-	2.4
Ages <65	39.6	36.7	43.2	39.8	37.0	43.3	34.5	32.2	37.3
Ages 65+	5.2	4.8	5.6	5.1	4.7	5.4	6.8	5.8	7.4
<u>Chronic Myeloid Leukemia</u>									
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	22.3	20.0	25.3	21.0	19.0	23.7	27.8 ^e	21.7 ^e	35.5 ^e
1978-1980 ^a	23.6	23.0	24.4	23.6	23.5	23.8	21.4 ^e	20.7 ^e	22.7 ^e
1981-1983 ^a	28.6	25.0	32.8	28.9	25.7	32.3	29.7	20.7 ^e	40.2 ^e
1984-1986 ^a	22.7	20.2	26.2	23.2	20.2	27.4	21.4	20.4 ^e	22.2 ^e
1987-1989 ^a	30.6	31.0	29.9	30.6	31.7	29.2	33.3 ^e	28.1 ^e	41.3 ^e
1990-1992 ^a	31.0	29.9	32.5	30.5	30.4	30.7	34.9 ^e	25.5 ^e	44.9 ^e
1993-1995 ^a	35.4	35.2	35.7	35.1	35.3	34.9	34.6 ^e	32.0 ^e	38.6 ^e
1996-2000 ^b	40.1	40.2	39.9	40.2	39.8	40.7	33.9	33.1 ^e	34.7 ^e
2001-2007 ^a	55.2 ^d	53.9 ^d	57.1 ^d	53.4 ^d	51.7 ^d	55.7 ^d	61.6 ^d	63.4 ^{de}	59.5 ^e
5-Year Period Survival (Percent) ^{bc}									
2007	58.6	58.4	58.9	56.9	57.0	56.6	60.4	59.9	60.5
5-Year Relative Survival (Percent), 2001-2007 ^b									
Age at Diagnosis:									
Ages <45	82.8	81.8	84.4	84.0	82.2	86.9	73.5	74.0	72.6 ^e
Ages 45-54	79.9	77.8	82.6	79.1	77.3	81.4	77.1 ^e	73.7 ^e	78.9 ^e
Ages 55-64	65.2	63.2	68.7	65.7	62.8	70.6	57.8 ^e	63.7 ^e	44.3 ^f
Ages 65-74	43.8	41.2	48.1	43.7	40.8	48.5	33.5 ^e	30.3 ^e	38.9 ^f
Ages 75+	26.6	24.9	27.8	26.6	24.7	27.9	27.4 ^e	21.8 ^e	31.6 ^e
Ages <65	77.2	75.4	79.7	77.2	75.0	80.7	70.7	71.5	68.9
Ages 65+	33.6	32.7	34.8	33.3	32.0	34.5	30.9	26.6 ^e	34.8 ^e

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2008.

^b SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^c Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^d The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 14.8
Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	3.4	1.9	6.4	3.4	2.0	5.8	1.8	0.0	5.6
1978-1980 ^b	3.3	2.2	5.4	3.3	2.2	4.8	3.6	3.0	5.0
1981-1983 ^b	3.7	3.1	5.0	4.0	3.2	5.2	2.8	2.1	4.7
1984-1986 ^b	5.7	3.7	9.5	5.7	3.7	9.1	4.3	2.1	9.2
1987-1989 ^b	4.8	3.2	7.9	5.6	3.4	9.2	2.7	1.6	4.9
1990-1992 ^b	5.6	4.9	7.0	6.3	5.2	8.3	2.6	2.0	3.6
1993-1995 ^b	5.6	5.3	6.2	5.3	5.0	5.8	4.0	2.7	7.4
1996-2000 ^b	9.4	9.1	10.0	8.7	8.0	10.2	5.9	6.3	4.8
2001-2007 ^b	15.0 ^e	15.3 ^e	14.4 ^e	14.6 ^e	15.1 ^e	13.3 ^e	9.9 ^e	8.5	14.0 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	16.0	16.1	15.7	15.3	15.7	14.4	10.9	8.8	16.5
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	29,672	21,113	8,559	20,080	14,294	5,786	3,376	2,461	915
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	39	39	40	39	39	38	37	37	39
Regional	26	27	24	25	26	23	28	28	27
Distant	19	19	18	18	18	18	22	23	20
Unstaged	16	15	18	17	16	20	13	12	14
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	30.6	27.6	38.1	33.7	30.4	40.9	18.0	15.3	25.7 ^f
Ages 45-54	18.8	18.2	22.4	19.4	19.0	21.9	12.3	10.1	22.6
Ages 55-64	16.1	15.0	20.1	16.4	15.2	20.9	8.2	6.4	13.3
Ages 65-74	11.8	11.1	13.1	10.0	9.7	10.6	7.9	5.0	13.7
Ages 75+	5.2	6.0	4.3	4.6	5.4	3.7	4.2	3.7	3.8
Ages <65	19.0	17.7	23.9	19.6	18.3	24.7	11.3	9.3	18.5
Ages 65+	8.6	8.9	8.2	7.4	7.8	6.6	6.5	4.9	8.9
Stage:									
All Stages	14.4	14.4	14.4	13.9	14.1	13.5	9.9	8.3	14.2
Localized	27.0	27.2	26.4	26.4	27.0	25.0	18.7	15.8	26.3
Regional	9.2	9.0	9.7	9.0	8.9	9.2	6.1	5.3	8.3
Distant	2.6	2.2	3.6	2.8	2.2	4.2	2.3	1.9	2.7
Unstaged	5.8	6.0	5.6	5.2	5.1	5.3	5.6	4.7	7.3

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^e The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 15.12
Cancer of the Lung and Bronchus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	8	7	11	5	5	6
1970-1973 ^a	-	-	-	10	9	14	7	6	10
1975-1977 ^b	12.3	11.1	15.5	12.3	11.1	15.6	11.4	10.7	13.8
1978-1980 ^b	12.8	11.4	16.3	12.9	11.5	16.3	11.8	9.8	17.9
1981-1983 ^b	13.2	11.6	16.5	13.4	11.8	16.7	11.4	10.2	14.9
1984-1986 ^b	12.9	11.3	16.0	13.1	11.4	16.3	11.2	10.5	12.8
1987-1989 ^b	13.1	12.0	15.0	13.4	12.1	15.4	11.0	10.8	11.2
1990-1992 ^b	13.6	12.1	16.0	14.0	12.5	16.2	10.4	9.3	12.5
1993-1995 ^b	14.4	12.6	16.9	14.6	12.7	17.2	12.8	11.3	15.5
1996-2000 ^b	15.0	13.1	17.4	15.2	13.2	17.5	12.6	11.1	14.8
2001-2007 ^b	16.3 ^e	14.2 ^e	18.8 ^e	16.7 ^e	14.5 ^e	19.2 ^e	13.3 ^e	12.1 ^e	15.0
5-Year Period Survival (Percent) ^{cd}									
2007	16.4	14.1	19.0	16.6	14.3	19.2	13.5	12.2	15.2
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	245,952	131,906	114,046	205,053	108,319	96,734	25,447	14,512	10,935
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	15	13	16	15	14	17	12	11	13
Regional	22	22	22	22	22	22	22	22	22
Distant	56	58	55	56	57	54	60	61	59
Unstaged	7	7	7	7	7	8	5	6	5
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	25.6	23.6	27.5	27.2	25.2	29.2	19.7	18.1	21.3
Ages 45-54	18.7	15.1	23.1	19.7	15.8	24.4	14.1	12.1	16.8
Ages 55-64	18.3	15.7	21.8	18.8	16.1	22.3	14.5	13.0	16.9
Ages 65-74	16.2	13.7	19.1	16.3	13.8	19.2	12.9	11.8	14.4
Ages 75+	11.3	9.9	12.7	11.5	10.1	12.9	8.5	7.3	9.6
Ages <65	18.9	16.0	22.6	19.6	16.5	23.4	14.8	13.0	17.3
Ages 65+	13.7	11.9	15.7	13.9	12.0	15.8	11.0	10.0	12.1
Stage:									
All Stages	15.6	13.5	18.0	15.9	13.7	18.3	12.9	11.6	14.5
Localized	52.2	47.4	56.7	52.9	48.2	57.2	44.1	40.0	48.6
Regional	24.3	22.1	27.0	24.3	22.1	26.9	22.5	21.3	24.0
Distant	3.6	3.0	4.2	3.5	2.9	4.2	3.4	3.2	3.7
Unstaged	8.1	7.1	9.2	7.7	6.5	8.9	10.3	9.8	11.0

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 15.13
Small Cell Cancer of the Lung and Bronchus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	3.6	3.1	4.8	3.7	3.1	4.9	3.7	3.8	3.6
1978-1980 ^a	4.2	3.1	6.5	4.3	3.3	6.5	3.1	2.4	5.0
1981-1983 ^a	4.6	3.6	6.3	4.6	3.7	6.1	5.4	4.2	8.4
1984-1986 ^a	4.6	3.5	6.3	4.7	3.6	6.5	3.6	2.2	5.6
1987-1989 ^a	5.0	3.9	6.6	5.1	3.9	6.8	4.0	3.3	5.1
1990-1992 ^a	5.4	4.6	6.4	5.5	4.6	6.6	3.9	3.9	3.9
1993-1995 ^a	6.4	5.2	7.8	6.3	5.1	7.7	6.8	4.5	9.9
1996-2000 ^b	5.9	5.1	6.8	5.9	4.9	7.0	4.7	4.6	4.9
2001-2007 ^a	6.2 ^d	4.5 ^d	7.9 ^d	6.2 ^d	4.3 ^d	8.2 ^d	5.0	4.7 ^d	5.2
5-Year Period Survival (Percent) ^{bc}									
2007	6.2	5.1	7.4	6.2	5.0	7.5	6.1	6.1	6.0
Stage Distribution (%) 2001-2007 ^b									
All Stages									
Number of cases	33,027	16,762	16,265	29,093	14,548	14,545	2,576	1,339	1,237
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	5	5	5	5	4	5	5	4	6
Regional	21	19	22	21	19	22	21	19	23
Distant	70	73	68	70	73	68	70	72	68
Unstaged	4	4	4	4	4	5	4	4	3
5-Year Relative Survival (Percent), 2001-2007 ^b									
Age at Diagnosis:									
Ages <45	9.7	8.7	10.8	9.2	8.1	10.3	13.1 ^e	10.9 ^e	18.0 ^e
Ages 45-54	8.6	6.2	11.5	8.8	6.5	11.6	6.1	3.9	9.0
Ages 55-64	7.8	5.7	10.1	7.8	5.6	10.2	6.9	6.9	6.4
Ages 65-74	5.5	4.7	6.2	5.6	4.5	6.5	3.5	4.2	2.9
Ages 75+	3.5	2.7	4.2	3.5	2.9	4.1	3.5	-	5.0
Ages <65	8.1	6.0	10.5	8.1	5.9	10.6	7.0	6.2	7.7
Ages 65+	4.6	3.8	5.3	4.7	3.8	5.5	3.5	3.3	3.7
Stage:									
All Stages	6.1	4.8	7.4	6.1	4.7	7.4	5.3	5.0	5.6
Localized	21.2	19.8	22.6	21.9	20.5	23.3	14.7	15.8 ^e	13.7 ^e
Regional	13.6	11.6	15.4	13.7	11.7	15.5	12.9	12.1	13.0
Distant	2.7	2.0	3.3	2.6	1.9	3.4	2.3	2.2	2.4
Unstaged	8.5	5.8	10.9	8.6	5.7	11.0	6.9	7.4	7.0

Note: Small Cell Cancer of the Lung and Bronchus includes histologies 8041-8045.

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^b SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^c Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival),

(2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^d The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 15.14
Non-Small Cell Cancer of the Lung and Bronchus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	13.7	12.4	17.5	13.8	12.4	17.6	12.3	11.4	15.9
1978-1980 ^a	14.5	12.9	18.4	14.6	13.1	18.5	12.9	10.7	19.8
1981-1983 ^a	15.0	13.1	19.0	15.3	13.4	19.4	12.2	11.0	15.9
1984-1986 ^a	14.7	12.8	18.4	15.0	13.0	18.8	12.3	11.6	14.3
1987-1989 ^a	14.8	13.6	17.1	15.2	13.7	17.6	12.0	11.9	12.3
1990-1992 ^a	15.3	13.5	18.2	15.8	14.0	18.6	11.3	9.9	14.0
1993-1995 ^a	15.9	13.8	18.8	16.3	14.0	19.3	13.6	12.1	16.4
1996-2000 ^b	16.6	14.4	19.4	16.9	14.7	19.7	13.6	11.8	16.3
2001-2007 ^a	18.0 ^d	15.7 ^d	20.7 ^d	18.6 ^d	16.2 ^d	21.3 ^d	14.3 ^d	12.8	16.2
5-Year Period Survival (Percent) ^{bc}									
2007	18.0	15.4	20.9	18.4	15.8	21.3	14.3	12.8	16.3
Stage Distribution (%) 2001-2007 ^b									
All Stages									
Number of cases	212,925	115,144	97,781	175,960	93,771	82,189	22,871	13,173	9,698
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	16	15	18	17	15	19	13	12	14
Regional	22	23	22	22	23	22	22	22	22
Distant	54	56	52	53	55	51	59	60	58
Unstaged	7	7	8	8	7	8	6	6	6
5-Year Relative Survival (Percent), 2001-2007 ^b									
Age at Diagnosis:									
Ages <45	27.4	25.3	29.4	29.6	27.5	31.7	20.1	18.5	21.8
Ages 45-54	20.5	16.7	25.2	21.9	17.6	27.1	14.9	13.0	17.7
Ages 55-64	20.4	17.5	24.3	21.2	18.1	25.1	15.5	13.7	18.4
Ages 65-74	18.0	15.1	21.6	18.3	15.3	21.9	14.0	12.5	16.1
Ages 75+	12.2	10.7	13.7	12.5	11.0	14.0	8.9	7.7	10.0
Ages <65	20.9	17.8	25.0	22.0	18.6	26.2	15.7	13.8	18.5
Ages 65+	15.0	12.9	17.3	15.3	13.2	17.5	11.8	10.6	13.2
Stage:									
All Stages	17.1	14.7	19.9	17.5	15.1	20.3	13.7	12.3	15.7
Localized	53.6	48.7	58.4	54.3	49.4	58.9	45.4	40.9	50.5
Regional	25.9	23.4	29.1	26.0	23.5	29.0	23.5	22.2	25.4
Distant	3.8	3.2	4.4	3.7	3.1	4.3	3.6	3.3	3.9
Unstaged	8.1	7.2	9.0	7.7	6.6	8.7	10.5	10.1	11.3

Note: Non-Small Cell Cancer of the Lung and Bronchus includes histologies 8000-8040, 8046-9049, 9056-9139, 9141-9589.

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2008.

^b SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Based on follow-up of patients into 2008.

^c Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival),

(2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^d The standard error is between 5 and 10 percentage points.

^e The standard error is greater than 10 percentage points.

^f - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 16.8
Melanoma of the Skin (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	60	51	68	-	-	-
1970-1973 ^a	-	-	-	68	62	75	-	-	-
1975-1977 ^b	82.0	77.6	86.3	82.0	77.8	86.2	58.0 ^f	-	-
1978-1980 ^b	82.8	77.8	87.7	82.9	77.9	87.8	59.8 ^g	-	-
1981-1983 ^b	82.8	78.4	87.3	82.7	78.4	87.2	61.9 ^f	-	-
1984-1986 ^b	86.7	82.6	91.1	86.4	82.2	91.0	70.3 ^g	-	-
1987-1989 ^b	88.1	85.0	91.5	88.0	85.0	91.3	79.4 ^f	-	90.3 ^f
1990-1992 ^b	89.3	87.0	91.8	89.3	87.1	91.8	61.8 ^f	-	-
1993-1995 ^b	89.7	87.3	92.6	89.5	87.0	92.6	68.2 ^f	64.0 ^f	-
1996-2000 ^b	91.6	90.1	93.3	91.5	89.9	93.4	72.7 ^f	68.7 ^f	76.0 ^f
2001-2007 ^b	93.0 ^e	91.1 ^e	95.2 ^e	93.0 ^e	91.0 ^e	95.3 ^e	73.4 ^f	72.3 ^f	73.7 ^f
5-Year Period Survival (Percent) ^{cd}									
2007	91.3	89.5	93.4	91.0	89.2	93.1	72.4	61.9	78.4
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	81,421	45,027	36,394	76,613	42,600	34,013	367	153	214
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	84	82	87	84	82	86	58	50	64
Regional	8	9	7	9	10	7	22	24	21
Distant	4	5	3	4	5	3	13	18	9
Unstaged	4	4	4	4	4	3	8	9	7
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	94.3	91.3	96.5	94.2	91.0	96.4	78.9	64.5 ^f	86.4
Ages 45-54	92.0	89.7	94.8	91.7	89.3	94.6	85.0 ^f	-	84.2 ^f
Ages 55-64	91.7	89.9	94.6	91.3	89.6	94.3	71.5 ^f	59.7 ^g	82.7 ^f
Ages 65-74	90.1	88.6	92.4	89.9	88.4	92.3	63.7 ^f	55.4 ^g	72.2 ^g
Ages 75+	84.9	84.8	85.1	84.7	84.6	84.8	62.2 ^f	62.2 ^g	60.1 ^g
Ages <65	92.8	90.3	95.5	92.5	89.9	95.4	77.8	68.5 ^f	84.3
Ages 65+	87.7	87.0	88.7	87.5	86.9	88.5	63.8 ^f	60.2 ^f	65.4 ^f
Stage:									
All Stages	91.2	89.2	93.7	90.9	88.9	93.5	72.4	65.2 ^f	77.4
Localized	98.2	97.6	98.8	98.0	97.4	98.7	94.8	90.3 ^f	96.3
Regional	61.7	58.4	66.9	62.1	58.7	67.5	41.4 ^f	44.3 ^g	37.9 ^g
Distant	15.2	14.3	16.9	15.0	14.3	16.4	25.2 ^f	19.6 ^g	-
Unstaged	74.6	71.1	78.9	73.5	70.1	77.5	53.3 ^g	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^e The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 17.4
Mesothelioma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	9.7	3.0	26.8	10.3	3.3	27.5 ^f	-	-	-
1978-1980 ^b	6.0	5.5	8.1	5.9	5.2	8.7	-	-	-
1981-1983 ^b	7.7	5.3	15.1	8.1	5.4	16.2	-	-	-
1984-1986 ^b	6.6	4.3	13.9	6.1	3.7	14.1	-	-	-
1987-1989 ^b	6.3	4.6	12.2	6.4	4.8	12.1	4.8	-	-
1990-1992 ^b	7.8	4.4	20.7	7.4	4.1	20.1	12.6 ^f	11.8 ^f	-
1993-1995 ^b	6.5	3.2	18.6	5.9	2.8	17.9	9.0	8.0 ^f	-
1996-2000 ^b	8.2	6.6	14.4	8.3	6.6	14.7	10.2	7.2	-
2001-2007 ^b	8.5	6.2 ^e	15.5	8.0	5.6 ^e	15.7	16.4 ^f	21.7 ^f	-
5-Year Period Survival (Percent) ^{cd}									
2007	8.0	6.1	14.6	7.5	5.5	14.5	13.1	14.4	-
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	38.9	33.8 ^f	44.3 ^f	34.7	31.2 ^f	38.7 ^f	-	-	-
Ages 45-54	16.6	13.0	22.3	15.8	12.4	21.1	28.6 ^f	-	-
Ages 55-64	8.5	6.4	16.1	8.8	6.2	18.6	6.7	9.5 ^f	-
Ages 65-74	6.5	6.4	7.5	6.4	6.1	7.7	10.2 ^f	11.1 ^f	-
Ages 75+	3.2	2.2	6.8	3.1	2.0	7.1	-	-	-
Ages <65	14.2	10.2	23.6	13.3	9.5	22.8	18.2	15.6 ^f	24.6 ^f
Ages 65+	4.6	4.0	7.0	4.5	3.7	7.3	8.1	9.7 ^f	-

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).^e The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).^f The standard error is between 5 and 10 percentage points.^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 18.8
Myeloma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	12	13	10	-	-	-
1970-1973 ^a	-	-	-	19	20	17	-	-	-
1975-1977 ^b	25.1	24.5	25.8	24.5	24.0	25.1	30.3	31.0	29.6
1978-1980 ^b	26.0	24.6	27.4	25.0	24.5	25.6	31.9	27.4	36.2
1981-1983 ^b	27.8	25.9	29.7	27.5	25.7	29.3	28.9	29.8	27.9
1984-1986 ^b	27.4	27.9	27.0	26.2	26.1	26.3	32.1	33.3	30.9
1987-1989 ^b	27.5	29.1	25.9	27.2	29.3	25.0	30.2	30.3	30.2
1990-1992 ^b	29.5	30.7	28.0	28.6	29.7	27.2	34.5	38.6	30.5
1993-1995 ^b	31.9	32.4	31.4	30.9	31.6	30.1	35.3	34.5	35.8
1996-2000 ^b	32.4	34.9	29.7	32.3	34.8	29.3	31.6	33.5	30.2
2001-2007 ^b	41.1 ^e	42.4 ^e	39.6 ^e	41.5 ^e	43.0 ^e	39.4 ^e	40.6 ^e	41.1 ^e	40.0 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	40.7	41.9	39.3	40.5	42.0	38.6	41.0	41.1	40.8
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	23,992	12,979	11,013	18,176	10,076	8,100	4,183	2,061	2,122
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	5	6	4	5	6	4	4	4	3
Regional	0	0	0	0	0	0	0	0	0
Distant	95	94	96	95	94	96	96	96	97
Unstaged	0	0	0	0	0	0	0	0	0
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	63.3	64.8	61.1	63.4	66.1	58.8	61.2	59.4 ^f	63.5
Ages 45-54	56.8	56.7	57.1	60.4	59.9	61.0	46.4	43.7	49.5
Ages 55-64	49.1	48.6	49.9	49.6	48.6	51.1	45.3	45.2	45.5
Ages 65-74	36.7	35.3	38.5	36.6	35.8	37.8	35.3	33.0	37.7
Ages 75+	23.7	24.4	23.1	23.4	24.5	22.3	24.1	22.0	25.5
Ages <65	53.3	53.1	53.6	54.6	54.2	55.2	48.0	46.6	49.5
Ages 65+	29.8	30.0	29.4	29.3	30.2	28.4	30.1	28.5	31.5
Stage:									
All Stages	39.7	40.6	38.6	39.5	40.8	37.9	39.1	38.3	39.9
Localized	68.4	72.7	61.0	67.8	72.0	60.2	62.4 ^f	71.3 ^f	52.5 ^f
Regional	-	-	-	-	-	-	-	-	-
Distant	38.2	38.6	37.7	37.9	38.6	36.9	38.3	37.0	39.4
Unstaged	-	-	-	-	-	-	-	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).^e The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).^f The standard error is between 5 and 10 percentage points.^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 19.8
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	31	31	31	-	-	-
1970-1973 ^a	-	-	-	41	39	43	-	-	-
1975-1977 ^b	46.7	45.6	47.7	47.0	46.4	47.6	48.4	42.6	54.9 ^f
1978-1980 ^b	48.1	46.2	50.1	48.1	46.4	49.9	51.1	47.1	56.7
1981-1983 ^b	50.8	50.5	51.2	51.1	50.7	51.4	49.9	49.4	50.4
1984-1986 ^b	51.8	50.2	53.5	52.1	50.8	53.7	46.9	44.5	50.1
1987-1989 ^b	51.1	47.8	55.1	51.6	48.4	55.5	46.4	41.7	52.1
1990-1992 ^b	50.9	46.8	56.0	51.7	47.7	56.7	42.1	38.2	47.6
1993-1995 ^b	52.7	48.9	57.6	53.4	50.0	57.8	41.9	35.8	53.5
1996-2000 ^b	60.6	58.5	63.1	61.4	59.5	63.1	53.6	50.1	58.4
2001-2007 ^b	69.5 ^e	68.1 ^e	71.2 ^e	70.7 ^e	69.6 ^e	72.0 ^e	62.1 ^e	57.9	67.0 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	68.1	66.9	69.5	68.8	68.1	69.7	59.3	54.6	64.6
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	82,967	44,394	38,573	70,207	37,574	32,633	6,155	3,328	2,827
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	29	27	30	28	27	30	28	26	30
Regional	15	15	16	15	15	16	14	13	15
Distant	48	50	45	48	50	46	50	54	46
Unstaged	8	8	9	8	8	9	8	7	9
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	76.4	73.2	81.7	78.3	75.0	84.1	62.3	58.7	67.8
Ages 45-54	76.6	73.2	81.7	78.5	75.3	83.2	62.2	55.2	72.5
Ages 55-64	73.6	69.9	78.3	74.5	71.0	78.9	64.4	58.8	71.1
Ages 65-74	67.4	64.4	70.5	68.0	65.2	70.9	58.5	50.8	65.5
Ages 75+	51.4	50.7	52.0	52.4	51.8	52.8	43.2	45.0	41.5
Ages <65	75.4	72.0	80.3	76.8	73.6	81.5	62.9	57.7	70.3
Ages 65+	58.6	57.4	59.6	59.2	58.2	60.1	52.2	48.8	54.4
Stage:									
All Stages	67.3	65.7	69.0	67.9	66.7	69.3	59.9	55.8	64.8
Localized	81.1	80.3	81.9	81.5	80.9	82.1	77.0	73.3	80.6
Regional	70.5	69.7	71.5	71.3	70.6	72.0	64.3	61.2	67.2
Distant	58.5	56.9	60.4	59.7	58.5	61.2	48.7	45.4	53.2
Unstaged	64.1	63.3	64.9	62.6	62.1	63.2	61.5	57.9	64.9

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.
^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.
^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
^e The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).
^f The standard error is between 5 and 10 percentage points.
^g The standard error is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 20.10
Cancer of the Oral Cavity and Pharynx (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	45	-	-	-	-	-
1970-1973 ^a	-	-	-	43	-	-	-	-	-
1975-1977 ^b	52.9	51.9	55.2	54.4	54.0	55.1	36.1	29.8	49.0
1978-1980 ^b	53.5	52.0	56.7	55.5	54.6	57.5	34.9	30.0	45.8
1981-1983 ^b	51.9	50.4	55.2	54.2	53.1	56.6	31.4	26.0	45.9
1984-1986 ^b	54.2	51.8	59.1	56.4	54.9	59.4	35.1	29.5	49.4
1987-1989 ^b	53.8	51.2	59.4	56.3	54.2	60.4	33.9	29.8	44.2
1990-1992 ^b	55.5	53.3	60.2	58.1	56.5	61.2	32.5	27.8	45.7
1993-1995 ^b	57.8	56.4	60.7	60.3	59.7	61.4	38.0	33.1	50.7
1996-2000 ^b	58.9	57.5	61.9	60.9	60.4	62.0	39.8	34.5	53.8
2001-2007 ^b	63.2 ^e	62.7 ^e	64.2 ^e	65.1 ^e	65.2 ^e	64.9 ^e	44.7 ^e	40.5 ^e	53.4
5-Year Period Survival (Percent) ^{cd}									
2007	61.5	60.8	63.1	63.2	63.0	63.7	41.7	36.8	52.0
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	43,977	30,455	13,522	35,891	25,082	10,809	4,148	2,874	1,274
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	33	29	42	34	30	43	21	17	32
Regional	46	50	38	46	50	38	50	54	42
Distant	15	16	13	14	14	12	23	24	19
Unstaged	6	6	7	6	6	7	6	5	6
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	78.0	74.5	84.0	79.8	77.0	85.0	62.7	52.7	76.3
Ages 45-54	66.1	64.7	70.6	69.5	68.3	73.7	40.8	37.9	47.5
Ages 55-64	61.0	59.7	65.4	63.1	61.9	66.9	38.8	36.8	45.9
Ages 65-74	55.2	54.3	57.2	57.0	57.0	57.1	35.1	28.9	50.5
Ages 75+	47.7	46.8	48.7	48.9	48.1	49.7	35.3	30.0	39.9
Ages <65	66.1	64.0	72.1	68.3	66.6	73.6	44.5	39.9	55.7
Ages 65+	51.7	51.3	52.3	53.1	53.3	52.8	35.3	29.2	45.7
Stage:									
All Stages	60.8	59.8	62.9	62.4	62.0	63.2	42.1	37.3	52.6
Localized	82.4	81.8	83.2	82.6	82.4	82.8	75.0	67.8	82.6
Regional	55.5	56.7	52.0	57.5	59.3	52.1	36.8	35.2	41.4
Distant	33.2	32.7	34.3	33.2	33.1	33.2	23.3	20.6	30.6
Unstaged	50.4	49.3	52.5	50.2	49.1	52.4	38.4	36.4	42.3 ^f

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^e The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 21.8
Cancer of the Ovary(Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<65	65+	All	<65	65+	All	<65	65+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	32	-	-	32	-	-
1970-1973 ^a	-	-	-	36	-	-	32	-	-
1975-1977 ^b	36.1	44.2	21.5	35.3	43.6	21.2	41.9	48.9	25.0 ^f
1978-1980 ^b	37.7	47.3	22.2	36.9	46.5	22.4	38.9	49.3	12.8
1981-1983 ^b	39.2	50.4	23.5	38.8	50.4	23.6	37.6	45.5	22.6
1984-1986 ^b	38.5	49.5	24.2	37.6	48.5	23.9	39.6	52.5	21.2
1987-1989 ^b	38.3	51.1	23.7	38.2	51.3	24.0	33.8	46.9	17.6
1990-1992 ^b	40.6	55.4	24.4	40.5	56.0	24.3	36.2	49.7	17.5
1993-1995 ^b	41.6	55.8	26.7	40.7	55.5	26.2	41.7	55.1	26.9
1996-2000 ^b	43.5	56.2	28.4	42.9	56.0	28.4	37.6	50.3	20.9
2001-2007 ^b	43.6 ^e	56.7 ^e	26.4 ^e	43.3 ^e	56.9 ^e	26.9 ^e	36.0	44.0	21.4
5-Year Period Survival (Percent) ^{cd}									
2007	43.9	56.9	26.8	43.7	56.8	27.5	35.4	45.8	18.2
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	31,316	17,355	13,961	26,519	14,269	12,250	2,276	1,348	928
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	15	21	7	14	20	7	15	20	7
Regional	17	20	13	17	20	13	14	15	13
Distant	62	56	70	63	57	70	63	59	68
Unstaged	7	4	10	7	3	10	8	6	12
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	73.5	-	-	73.9	-	-	66.8	-	-
Ages 45-54	58.0	-	-	59.0	-	-	40.7	-	-
Ages 55-64	45.7	-	-	46.2	-	-	31.7	-	-
Ages 65-74	35.0	-	-	35.7	-	-	23.1	-	-
Ages 75+	20.5	-	-	21.2	-	-	12.4	-	-
Ages <65	56.9	-	-	57.1	-	-	45.5	-	-
Ages 65+	27.0	-	-	27.5	-	-	18.0	-	-
Stage:									
All Stages	43.8	56.9	27.0	43.7	57.1	27.5	34.9	45.5	18.0
Localized	92.5	93.4	89.0	92.6	93.4	89.5	88.6	91.4	73.3 ^f
Regional	72.0	79.9	55.6	73.0	81.1	57.2	52.7	63.1	34.8 ^f
Distant	26.9	35.6	18.1	27.5	36.4	18.8	18.1	24.3	9.3
Unstaged	22.4	48.3	10.8	21.1	46.6	11.0	25.6	46.6 ^f	10.5

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival),

(2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).

^e The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 22.8
Cancer of the Pancreas (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	1	1	2	1	0	3
1970-1973 ^a	-	-	-	2	2	2	2	0	3
1975-1977 ^b	2.4	2.6	2.2	2.5	2.6	2.3	2.3	2.6	1.9
1978-1980 ^b	2.8	2.7	3.0	2.5	2.6	2.5	5.6	4.1	7.0
1981-1983 ^b	2.8	2.4	3.2	2.6	2.2	3.0	3.6	3.7	3.2
1984-1986 ^b	2.9	2.3	3.4	2.6	2.1	3.1	4.6	3.9	5.1
1987-1989 ^b	3.5	3.3	3.8	3.2	3.1	3.3	5.5	5.1	5.8
1990-1992 ^b	4.3	4.1	4.5	4.4	4.2	4.6	3.7	3.2	4.1
1993-1995 ^b	4.0	3.7	4.3	3.9	3.6	4.3	3.4	3.3	3.4
1996-2000 ^b	4.6	4.7	4.5	4.3	4.8	3.8	4.6	3.6	5.4
2001-2007 ^b	5.6 ^e	5.3 ^e	5.9 ^e	5.9 ^e	5.8 ^e	6.1 ^e	3.8 ^e	3.3 ^e	4.3 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	5.8	5.2	6.4	5.8	5.3	6.3	4.9	3.9	5.8
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	47,456	23,226	24,230	38,603	19,122	19,481	5,236	2,327	2,909
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	8	7	9	8	7	9	9	7	10
Regional	27	26	27	27	26	27	25	25	25
Distant	53	56	50	53	56	50	56	60	53
Unstaged	13	11	14	13	11	15	11	8	12
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	21.7	15.8	28.9	20.8	15.7	27.2	20.2	14.2	27.2 ^f
Ages 45-54	8.9	7.6	10.9	8.7	8.0	9.8	8.1	5.6	11.2
Ages 55-64	6.2	5.2	7.6	6.5	5.5	7.9	4.2	2.4	6.3
Ages 65-74	4.9	4.6	5.2	5.1	4.9	5.3	2.9	2.6	2.9
Ages 75+	3.0	3.1	2.9	3.2	3.0	3.3	1.5	3.3	1.1
Ages <65	8.5	6.9	10.8	8.4	7.1	10.4	7.0	4.6	9.9
Ages 65+	3.8	3.8	3.7	3.9	3.9	3.9	2.2	2.7	1.9
Stage:									
All Stages	5.5	5.1	5.8	5.5	5.2	5.7	4.4	3.8	5.0
Localized	21.5	19.6	23.0	21.7	20.4	22.5	15.2	11.3	17.8
Regional	8.7	8.5	8.9	8.8	8.6	8.9	7.6	6.9	8.1
Distant	1.8	1.9	1.7	1.8	1.9	1.7	1.4	1.4	1.3
Unstaged	4.2	4.6	3.8	4.1	4.5	3.7	5.1	5.2	5.0

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).^e The standard error is between 5 and 10 percentage points.^f The standard error is greater than 10 percentage points.^g -
Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 23.8
Cancer of the Prostate (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Males			White Males			Black Males		
	All	<65	65+	All	<65	65+	All	<65	65+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	50	-	-	35	-	-
1970-1973 ^a	-	-	-	63	-	-	55	-	-
1975-1977 ^b	68.3	73.7	66.6	69.0	75.4	67.1	61.0	62.2	60.5
1978-1980 ^b	70.5	75.5	69.1	71.7	77.1	70.1	62.1	65.2	60.8
1981-1983 ^b	72.4	76.3	71.4	73.5	77.9	72.3	63.2	65.4	62.3
1984-1986 ^b	75.5	77.6	75.0	76.8	79.3	76.2	65.8	67.6	65.2
1987-1989 ^b	83.2	83.3	83.2	84.8	84.8	84.8	71.5	72.7	71.2
1990-1992 ^b	93.3	93.1	93.3	94.4	94.1	94.5	84.6	86.6	83.8
1993-1995 ^b	95.4	95.9	95.2	96.1	96.6	95.9	91.7	93.2	90.9
1996-2000 ^b	98.3	98.7	98.1	98.9	99.1	98.7	95.6	97.2	94.3
2001-2007 ^b	99.9 ^e	99.7 ^e	99.9 ^e	99.9 ^e	99.8 ^e	99.9 ^e	97.9 ^e	99.1 ^e	96.2 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	99.4	99.2	99.3	99.6	99.3	99.5	96.5	98.7	94.1
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	332,115	132,852	199,263	263,353	103,366	159,987	41,690	21,015	20,675
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	81	79	83	81	79	83	80	79	82
Regional	12	17	8	12	18	8	11	15	7
Distant	4	3	5	4	3	5	6	4	7
Unstaged	3	1	4	3	1	4	3	1	4
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	96.4	-	-	96.1	-	-	96.6	-	-
Ages 45-54	98.2	-	-	98.3	-	-	97.6	-	-
Ages 55-64	99.5	-	-	99.7	-	-	98.4	-	-
Ages 65-74	100.0	-	-	100.0	-	-	97.8	-	-
Ages 75+	97.4	-	-	98.0	-	-	85.9	-	-
Ages <65	99.1	-	-	99.3	-	-	98.2	-	-
Ages 65+	99.5	-	-	99.7	-	-	94.1	-	-
Stage:									
All Stages	99.4	99.1	99.5	99.7	99.3	99.7	96.2	98.2	94.1
Localized	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Regional	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.6
Distant	28.7	30.8	27.9	28.1	30.4	27.4	27.9	30.4	26.2
Unstaged	69.9	83.4	66.8	68.8	83.4	65.9	58.8	74.4	52.8

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 24.8
Cancer of the Stomach (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	11	10	13	8	5	14
1970-1973 ^a	-	-	-	13	12	14	13	15	10
1975-1977 ^b	15.3	14.5	16.6	14.2	13.2	15.9	16.1	16.1	16.2
1978-1980 ^b	16.1	14.3	19.0	15.5	13.7	18.3	16.5	15.6	18.1
1981-1983 ^b	17.3	16.5	18.7	16.2	15.4	17.6	16.6	16.5	16.7
1984-1986 ^b	17.8	15.7	21.1	17.0	14.6	20.9	19.1	17.0	22.1
1987-1989 ^b	19.9	17.1	24.6	18.5	15.6	23.3	18.8	16.6	22.5
1990-1992 ^b	21.0	18.2	25.5	18.8	16.1	23.2	22.9	22.1	24.0
1993-1995 ^b	21.1	20.1	22.7	19.9	18.9	21.7	19.5	17.5	22.4
1996-2000 ^b	22.7	21.7	24.3	21.0	19.5	23.5	22.1	21.2	23.3
2001-2007 ^b	27.1 ^e	25.2 ^e	30.3 ^e	26.1 ^e	24.2 ^e	29.3 ^e	27.2 ^e	23.2 ^e	32.6 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	27.1	25.3	29.7	25.7	24.0	28.4	26.3	22.0	31.9
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	32,684	19,724	12,960	23,329	14,422	8,907	4,078	2,272	1,806
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	24	22	26	23	22	26	24	22	28
Regional	31	33	28	31	33	27	30	31	28
Distant	34	35	33	35	36	34	34	37	30
Unstaged	11	10	13	11	10	13	12	10	14
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	30.5	28.0	33.6	28.9	25.7	33.3	33.9	30.7	37.9
Ages 45-54	29.8	28.0	33.3	27.4	25.7	30.6	32.5	27.9	39.9
Ages 55-64	28.0	25.5	33.6	25.6	23.8	29.9	29.7	24.5	39.6
Ages 65-74	28.4	26.8	31.4	27.4	25.8	30.8	24.8	21.5	29.6
Ages 75+	21.6	19.3	24.0	21.0	18.9	23.3	16.9	12.7	19.1
Ages <65	29.1	26.7	33.5	26.8	24.7	30.9	31.5	26.8	39.4
Ages 65+	24.4	22.8	26.5	23.6	22.1	25.8	20.6	17.8	23.1
Stage:									
All Stages	26.3	24.5	29.0	24.8	23.2	27.5	25.5	22.5	29.4
Localized	61.4	58.9	64.7	59.9	57.3	63.4	57.5	55.1	59.9
Regional	27.8	26.6	29.9	26.4	25.4	28.4	26.5	24.3	29.4
Distant	3.6	3.6	3.5	3.2	3.3	3.2	4.8	3.7	6.2
Unstaged	16.4	13.4	20.0	15.0	12.3	18.3	15.1	11.1	18.7

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).^e The standard error is between 5 and 10 percentage points.^f The standard error is greater than 10 percentage points.^g -
Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 25.8
Cancer of the Testis (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Males			White Males			Black Males		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	63	-	-	-	-	-
1970-1973 ^a	-	-	-	72	-	-	-	-	-
1975-1977 ^b	82.7	83.3	77.7	82.6	83.3	77.4	-	-	-
1978-1980 ^b	88.9	89.5	82.4	89.2	89.8	83.4	73.2 ^f	78.0 ^f	-
1981-1983 ^b	92.2	92.7	86.3	92.4	92.9	86.4	87.7 ^f	84.7 ^f	-
1984-1986 ^b	92.6	93.6	80.5	93.0	94.0	80.7	87.0 ^f	89.4 ^f	-
1987-1989 ^b	95.1	95.0	95.7	95.4	95.3	95.3	88.4 ^f	87.8 ^f	-
1990-1992 ^b	95.8	95.8	93.8	96.2	96.1	94.7	83.5 ^f	-	-
1993-1995 ^b	95.7	96.2	86.6	96.0	96.5	87.8	88.0	89.4	-
1996-2000 ^b	95.7	96.3	88.7	95.9	96.4	88.9	90.6	90.9	-
2001-2007 ^b	96.4 ^e	96.8 ^e	93.0 ^e	97.0 ^e	97.1 ^e	93.9 ^e	85.9	86.8	-
5-Year Period Survival (Percent) ^{cd}									
2007	95.3	95.6	92.6	95.6	95.8	93.3	88.8	87.9	-
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	14,025	12,661	1,364	12,880	11,628	1,252	377	339	38
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	70	70	70	70	70	70	59	60	53
Regional	17	17	16	17	17	16	21	21	24
Distant	12	12	11	11	11	11	19	19	16
Unstaged	1	1	3	1	1	3	2	1	8
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	95.7	-	-	96.0	-	-	87.8	-	-
Ages 45-54	95.6	-	-	96.1	-	-	84.1 ^f	-	-
Ages 55-64	90.4	-	-	91.1	-	-	-	-	-
Ages 65-74	86.8	-	-	84.8	-	-	-	-	-
Ages 75+	58.1 ^g	-	-	67.3 ^g	-	-	-	-	-
Ages <65	95.5	-	-	95.9	-	-	86.6	-	-
Ages 65+	78.3 ^f	-	-	81.3 ^f	-	-	-	-	-
Stage:									
All Stages	95.3	95.6	91.8	95.7	95.9	93.0	86.5	87.8	72.5 ^f
Localized	99.0	99.2	96.9	99.1	99.3	97.3	98.5	98.6	-
Regional	96.2	96.0	96.5	96.9	96.5	97.9	84.9	88.4	-
Distant	72.0	73.1	60.2	73.0	74.1	61.3	51.1 ^f	50.8 ^f	-
Unstaged	85.5	91.9	59.0 ^f	87.1	92.4	63.1 ^g	-	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

^g - Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 26.8
Cancer of the Thyroid (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	83	75	87	-	-	-
1970-1973 ^a	-	-	-	86	82	87	-	-	-
1975-1977 ^b	92.2	91.1	92.5	91.9	90.7	92.3	90.3	-	91.5
1978-1980 ^b	92.1	87.3	93.6	91.5	87.6	92.7	90.2	68.0 ^g	95.5
1981-1983 ^b	93.7	92.2	94.0	93.1	90.9	93.8	96.4	100.0	93.2
1984-1986 ^b	93.1	89.9	94.2	93.2	89.5	94.2	89.4	85.5 ^f	90.4
1987-1989 ^b	94.5	91.6	95.3	94.2	91.7	95.0	92.2	91.2 ^f	92.2
1990-1992 ^b	94.3	90.5	95.6	95.0	91.7	96.0	85.9	84.7 ^f	86.3
1993-1995 ^b	95.4	91.7	96.6	95.5	91.6	96.9	93.2	88.1 ^f	94.3
1996-2000 ^b	96.1	92.9	97.0	96.4	93.4	97.4	93.7	85.2	95.2
2001-2007 ^b	97.3 ^e	94.4 ^e	98.1 ^e	97.6 ^e	94.7 ^e	98.5 ^e	95.2	93.0	95.5
5-Year Period Survival (Percent) ^{cd}									
2007	97.4	94.3	98.3	97.8	94.5	98.6	94.7	89.4	95.8
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	45,390	10,391	34,999	37,433	8,851	28,582	2,672	499	2,173
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	68	58	71	68	59	71	75	65	78
Regional	25	31	23	25	31	23	15	20	14
Distant	5	8	4	5	8	4	7	12	6
Unstaged	2	3	2	2	2	2	2	3	2
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	99.5	98.5	99.7	99.5	98.5	99.8	98.8	96.4	99.2
Ages 45-54	98.8	96.2	99.5	99.1	96.5	99.7	95.9	89.8	97.0
Ages 55-64	96.6	93.9	97.7	96.9	94.0	98.0	93.4	88.0	94.6
Ages 65-74	92.0	87.6	94.0	92.6	88.4	94.6	87.4	84.3 ^f	87.9
Ages 75+	82.2	77.3	83.7	83.4	77.1	84.3	70.0 ^f	69.7 ^g	69.9 ^f
Ages <65	98.8	96.6	99.3	98.9	96.7	99.5	97.0	92.4	97.8
Ages 65+	88.6	84.3	90.3	89.4	84.8	91.0	82.2	80.1 ^f	82.3
Stage:									
All Stages	97.2	94.2	98.1	97.5	94.4	98.3	94.9	90.9	95.7
Localized	99.8	99.6	99.9	99.9	99.7	99.9	99.1	95.7	99.4
Regional	96.8	94.9	97.6	96.8	94.4	97.8	95.5	95.4	94.4
Distant	55.4	48.3	59.5	54.6	46.7	59.7	49.2	49.6 ^f	48.5 ^f
Unstaged	87.6	80.3	90.1	86.7	78.4	89.4	77.7 ^f	-	77.0 ^f

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).
The difference between 1975-1977 and 2001-2007 is statistically significant (p<.05).^e The standard error is between 5 and 10 percentage points.^f The standard error is greater than 10 percentage points.^g -
Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 27.8
Cancer of the Urinary Bladder (Invasive and *In Situ*)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	53	53	53	24	24	24
1970-1973 ^a	-	-	-	61	61	60	36	38	27
1975-1977 ^b	72.5	74.0	68.4	73.5	74.6	70.3	50.3	56.5	38.1 ^f
1978-1980 ^b	74.1	75.3	70.4	74.9	75.7	72.4	54.6	62.7	40.4
1981-1983 ^b	77.0	78.4	73.1	77.7	78.9	74.3	59.7	64.9	47.6 ^f
1984-1986 ^b	76.9	78.3	72.9	77.5	78.7	73.9	59.6	62.6	52.9
1987-1989 ^b	79.2	81.6	72.2	80.0	82.2	73.5	62.5	67.6	52.6
1990-1992 ^b	79.6	82.1	72.2	80.6	83.0	73.4	63.4	66.1	58.8
1993-1995 ^b	80.6	82.4	75.4	81.4	82.8	77.3	60.0	67.0	45.8
1996-2000 ^b	79.4	80.6	76.1	80.3	81.3	77.3	62.6	66.0	55.9
2001-2007 ^b	80.2 ^e	81.8 ^e	75.6 ^e	81.1 ^e	82.4 ^e	77.2 ^e	64.1 ^e	67.9 ^e	55.9 ^e
5-Year Period Survival (Percent) ^{cd}									
2007	77.9	79.7	72.3	78.2	79.7	73.4	63.4	69.4	52.9
Stage Distribution (%) 2001-2007 ^c									
All Stages									
Number of cases	79,277	59,333	19,944	71,146	53,650	17,496	3,827	2,438	1,389
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
In Situ	51	52	49	51	52	50	38	42	31
Localized	35	35	35	35	35	34	39	38	41
Regional	7	7	8	7	7	8	12	10	13
Distant	4	3	5	4	3	5	8	6	10
Unstaged	3	3	3	3	2	3	4	4	4
5-Year Relative Survival (Percent), 2001-2007 ^c									
Age at Diagnosis:									
Ages <45	89.3	89.9	87.9	90.0	90.2	89.4	76.2	77.9	71.4 ^f
Ages 45-54	85.0	85.1	84.4	85.6	85.4	86.2	72.3	76.3	60.3 ^f
Ages 55-64	84.1	84.6	82.3	84.6	84.9	83.5	69.6	72.6	62.3
Ages 65-74	79.6	80.5	76.3	79.9	80.5	78.0	67.9	74.9	54.8
Ages 75+	70.8	74.1	62.7	71.5	74.6	63.5	51.8	56.0	46.0
Ages <65	84.9	85.2	83.6	83.4	85.5	84.9	71.5	74.7	63.1
Ages 65+	74.6	77.0	67.8	75.1	77.2	69.0	59.6	66.2	50.2
Stage:									
All Stages	78.1	79.9	72.6	78.5	80.1	73.8	64.4	70.3	54.0
In Situ	96.6	96.9	95.7	96.7	96.9	96.2	92.3	95.1	85.9
Localized	70.7	73.0	63.6	70.9	73.0	64.3	61.4	66.5	53.0
Regional	34.6	36.0	30.9	34.4	35.6	31.2	31.6	35.4	25.8
Distant	5.4	5.9	4.4	5.5	6.1	4.2	5.1	3.5	5.4
Unstaged	49.1	53.2	39.9	46.7	51.3	36.1	41.9 ^f	43.5 ^f	37.1 ^f

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2008.

^c SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Based on follow-up of patients into 2008.

^d Period survival provides a 2007 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2005-2007: 0-1 year survival), (2004-2006: 1-2 year survival), (2003-2005: 2-3 year survival), (2002-2004: 3-4 year survival), (2001-2003: 4-5 years survival).


^e The difference between 1975-1977 and 2001-2007 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Childhood Cancer 5-Year Observed Survival (%) by ICCC Group^a and Race/Ethnicity Both Sexes, Under 20 Years of Age, 2001-2007



Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey).

International Classification of Childhood Cancer is based on ICD-O-3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer. April 1, 2005; Vol 103, No. 7, pg 1457-1467.

^a Excludes myelodysplastic syndromes (MDS) and benign brain tumors.

^b American Indian/Alaska Native. Survival data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Survival data for Hispanics are based on NHIA and excludes cases from the Alaska Native Registry.